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Abstract 
 
 
This work aimed the development of biological and synthetic affinity ligands for human 
serum albumin (HSA). The first approach was to optimize the expression of a biological ligand, 
named WW Clone 3, which was previously selected from a phage display library using HSA as 
a target. The expression of WW Clone 3 in Escherichia coli strain BL21 (DE3) was attempted at 
three different temperatures (18ºC, 25ºC and 30ºC), with 1mM Isopropyl-β-D-
thiogalactopyranoside (IPTG). The best temperature for cell growth was 30ºC, producing a 
larger amount of total protein with approximately 45 mg/ml in the soluble fraction and 10mg/ml 
in the insoluble fraction. However, WW Clone 3 was difficult to produce.  
The second approach was to develop synthetic affinity ligands to HSA based on solid-
phase synthesis of combinatorial libraries. The libraries were designed on the basis of amino 
acids from protein PAB (Peptostreptococcal albumin-binding) and drugs that bind naturally to 
the domain II of HSA. Two libraries were synthesized through the Ugi and Triazine reaction with 
88 and 64 ligands, respectively.   
The libraries were screened for binding to pure HSA and pure immunoglobulin G 
(IgG), to assess the selectivity towards HSA. The ligands that had the highest affinity for HSA 
and lowest affinity for IgG were re-screened to confirm the results. Two ligands, A3A2 and A6A5 
from the Triazine library appeared as the most selective for HSA and therefore more promising 
for the capture of this protein.  
 
 
 
Keywords: Human serum albumin; biological ligands; WW domain; synthetic ligand, 
combinatorial chemistry; affinity chromatography. 
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Resumo 
 
Este trabalho teve como objetivo o desenvolvimento de ligandos de afinidade 
biológicos e sintéticos para albumina do soro humano (ASH). A primeira abordagem foi a de 
otimizar a expressão de um ligando biológico, intitulado WW Clone 3, que foi previamente 
selecionado a partir de uma biblioteca de phage display utilizando ASH como alvo. A expressão 
de WW Clone 3 em Escherichia coli estirpe BL21 (DE3) foi realizada a três temperaturas 
diferentes (18ºC, 25ºC e 30ºC), com 1mM isopropil-b-D-galactosídeo (IPTG). A temperatura 
mais adequada para o crescimento celular foi de 30ºC, produzindo uma maior quantidade de 
proteína total, com aproximadamente 45mg/ml na fracção solúvel e 10mg/ml na fracção 
insolúvel. No entanto, WW Clone 3 foi difícil de produzir. 
A segunda abordagem foi desenvolver bibliotecas combinatórias de ligandos de 
afinidade sintéticos, em fase sólida, para ASH. As bibliotecas foram concebidas com base nos 
aminoácidos da proteína PAB (Peptostreptococcal albumin-binding) e drogas que se ligam 
naturalmente ao domínio II da ASH. Duas bibliotecas foram sintetizadas através da reação de 
Ugi e Triazina com 88 e 64 ligandos, respectivamente. 
Foram realizados avaliações das interações das bibliotecas para ligação à ASH pura e 
posteriormente à imunoglobulina G (IgG) pura para aferir acerca da seletividade dos ligandos 
para ASH. Os ligandos que apresentaram a maior afinidade para a ASH e menor afinidade 
para IgG foram reavaliados para confirmar os resultados obtidos. Dois ligandos, A3A2 e A6A5 
da biblioteca de Triazina, mostraram ser mais seletivos para ASH e, portanto mais promissores 
para a purificação desta proteína. 
 
 
 
 
 
Palavras-chave: Albumina do soro humano; ligandos biológicos; domínio WW; ligando 
sintético, química combinatória; cromatografia de afinidade. 
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Figure I.1 : Three-dimensional structure of human serum albumin. Representation in ribbon 
models of HSA determined in 1999 by X-ray crystallography with a high resolution (2.5Å) 
Structure of HSA with the subdomains in different colors (subdomain IA, in orange; 
subdomain IB, in yellow; subdomain IIA, in dark green; subdomain IIB, in light green; 
subdomain IIIA, in dark blue; subdomain IIIB in light blue). Image built in UCSF Chimera 
software (PDB code: 1AO6) (Sugio et al, 1999). 3 
 
Figure I.2: Structure of HSA with ligand binding sites. Representation in ribbon models of 
HSA with myristic acid and azapropazone determined in 2005 by X-ray crystallography 
with a high resolution (2.5 Å). The six subdomains of HSA are colored as follows: 
subdomain IA: orange; subdomain IB: yellow; subdomain IIA: dark green; subdomain IIB: 
light green; subdomain IIIA: dark blue; subdomain IIIB: light blue. The drug site II is 
occupied by myristic acid (fatty acid) and the drug site II is occupied by azapropazone 
(drug), both white. Oxygen atoms are colored red and nitrogen atoms blue. Image built in 
UCSF Chimera software (PDB code: 2BXI) (Ghuman et al, 2005). 7 
 
Figure I.3: Three-dimensional structure of the human neonatal Fc receptor. 
Representation in ribbon models of the human neonatal Fc receptor determined in 2010 by 
X-ray crystallography with a high resolution (2.6 Å). The red is the heavy chain called IgG 
receptor, and the light chain β2- microglobulin in orange. Image built in UCSF Chimera 
software (PDB code: 3M1B) (Mezo et al, 2010). 8 
 
Figure I.4: FcRn mediated pH- dependent, recycling and transport of IgG and HSA. 
Plasma proteins are pinocytosed along with a variety of other constituents at neutral pH 
(pH 7.4) (light blue shading), then move to the acidic endosomal (pH 6.0) (pink shading) 
compartments where IgG (structure in dark blue) and albumin (structure in red) bind to 
FcRn receptor (structure in green) with high affinity at distinct binding sites. Unbound 
plasma proteins (purple lozenge shaped) or excess ligands, when FcRn is satured, are 
destined for degradation in lysosomes (circle in grey), while bound complex is sent to the 
cell membrane where IgG and albumin dissociate from FcRn at physiological pH, providing 
a longer survival for the two proteins. Image built in UCSF Chimera software (PDB code: 
3M1B, 1AO6 and 1IGT) (Image adapted from Kontermann, 2012). 9 
 
Figure I.5: Structure of human FcRn complexed with HSA. Representation in ribbon models 
of the human FcRn complexed with HSA determined in 2014 by X-ray crystallography with 
a high resolution (3.0 Å). (A) FcRn receptor with receptor IgG heavy chain bound mainly to 
the domain III of HSA. (B) Detail on the residue histidine 161 (grey) from FcRn, contributor 
to the pH-dependent process. Image built in UCSF Chimera software (PDB code: 4N0F) 
(Oganesyan et al, 2014). 9 
 
Figure I.6: An overview of the streptococcal protein G (SpG). The HSA and Imunoglobulin 
Binding sites are in different domainsof the protein. However, both have three homologous 
domains. Nomenclature according to Ståhl and Nygren (1999) (adapted from Linhult et al, 
2002). 13 
 
Figure I.7: Three-dimensional structure of albumin binding domain from Protein G. The 
structure was determined by NMR spectroscopy in 2002. ABD structure with three-helix 
bundle. The helices 2 and 3 are red with the code of the respective amino acids, site of 
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highest affinity to HSA. Image built in UCSF Chimera software (PDB code: 1GJS) 
(Johansson et al, 2002). 14 
 
Figure I.8: Structure of the albumin-binding GA module. The structure was determined by 
NMR spectroscopy in 1997. Three- dimensional structure of GA module with the helix 1 in 
green and the helices 2 and 3 are red with the code of the respective amino acids, site of 
highest affinity to HSA. Image built in UCSF Chimera software (PDB code: 1GAB) 
(Johansson et al, 1997). 15 
 
Figure I.9: Structure of the GA module complexed with HSA. Representation in ribbon 
models of HSA determined in 2004 by X-ray crystallography with a high resolution (2.7 Å).  
(A) The GA module binds in the domain II of HSA. The HSA molecule is shown in blue and 
the GA module in red. (B) Detail in the interactions between HSA side chains and the GA 
helices (red) pack at almost right angles to helices 3, 4, and 7 (h3, h4, and h7) in HSA 
domain II. Image built in UCSF Chimera software (PDB code: 1TF0) (Lejon et al ,2004). 16 
 
Figure I.10: Schematic representation of the procedures performed in this study.  Image 
for the structures of the protein PAB and IgG were built in UCSF Chimera software (PDB 
code: 1AO6, 1GAB and 1IGT). 18 
 
Figure II.1: Structure of the WW Clone 3. (A) Structure of the WW prototype (blue), with three-
stranded antiparallel β- sheet, and the amino acids proline and tryptophan are in yellow 
and green, respectively. (B) Structure of the WW Clone 3 (red) based on WW prototype. 
The loops were randomized. In the loop I, three amino acids were added and in the loop II, 
two amino acids were added. (C) The structure of WW prototype (blue) and the WW Clone 
3 (red) overlapped. The loops from WW Clone 3 are increased compared to the WW 
prototype. (D) Protein Sequence of WW Clone 3 has five amino acids in loop I, and four 
amino acids in loop II. Images built in UCSF Chimera software, the structure of the WW 
prototype with PDB code: 1E0M (Macias et al, 2000). 23 
 
Figure II.2: Scheme of the cloning strategy of WW Clone 3 into pET 21c and the DNA 
sequence of WW Clone 3 with His-tag. (A) Schematic representation of the cloning 
strategy of gene codifying WW Clone 3 into pET 21c vector. (B)Protein sequence from WW 
Clone 3 with his-tag, and the DNA sequence with the nucleic acids that initiate the WW 
Clone 3 gene in highlighted. 26 
 
Figure II.3: Agarose gel purification of the DNA fragment. (A) 2% agarose gel of the insert 
WW Clone 3 with a fragment of 160bp. (B) 1% agarose gel of the pET 21c with a fragment 
of 5400bp. It was used the marker NzyDNA ladder V to the 2% agarose gel and the marker 
Nzy DNA ladder III to the 1% agarose gel. 32 
 
Figure II.4: Screening of the Clones NC, 3:1 and 5:1. It was possible verify one clone 
positive, 5:1-2, that has a fragment of 160bp that corresponding to the WW Clone 3. It was 
used the marker NzyDNA ladder V. 33 
 
Figure II.5: Screening of the clone 5:1-2. A greater amount of sample was added, showing 
that the clone 5:1-2 is a positive clone. It was used the marker NzyDNA ladder V. 34 
 
Figure II.6: Graphic of cell growth by measuring the absorbance at 600nm. (S) Optical 
density values obtained during the growth of the WW Clone 3, by Spectrophotometer. (M) 
xix 
 
Optical density values obtained during the growth of the WW Clone 3, by a multiplate 
reader. 35 
 
Figure II.7: SDS-Page with polyacrylamide gel 17.5% to verify the expression of the clone 
WW Clone 3. Polyacrylamide gel (17, 5%) from electrophoresis, stained with Coomassie 
blue with the samples of 18ºC, 25ºC and 30ºC. The control used was the protein WW Pin1. 
It was used the marker Precision Plus Protein Dual Color Standards. 35 
 
Figure II.8: Western Blotting method and Total protein quantification. (A) Western blotting 
membrane from the tris-tricine gel for all samples in study, with a band of a positive control, 
GFP-Pin1. It was used the marker Precision Plus Protein dual color standards. SF (soluble 
fraction); IF (insoluble fraction). (B) Column chart for total protein concentration obtained by 
BCA test. The concentration for soluble fraction is in blue and for insoluble fraction in 
orange. 36 
 
Figure III.1: The solid phase synthesis of Triazine reaction. For occur the combinatorial 
synthesis of a Triazine-based ligand library, the cyanuric chloride compound, will be 
undergoes three nucleophilic substitution (denoted by Nü), and these nucleophiles can be 
amines, hydroxyls, thiols and others. For the first substitution, a solid matrix (sphere) with a 
nucleophile will react with cyanuric chloride at 0°C for 1 hour. Subsequently two other 
nucleophilic substitutions will occur: R1 at 30 ° C for 24 hours and R2 at 80ºC for 48 hours. 
R1 and R2 can contain a varied functional group (Lowe et al, 2000). 41 
 
Figure III.2: Mechanism for the Ugi reaction. The reaction begins with an interaction between 
the amine and the aldehyde or ketone in a solid matrix, to give the corresponding imine (1). 
The imine will react in an acid-base reaction with the carboxylic acid to form an iminium ion 
(2), which is posteriorly arrested by the isocyanide to obtain a nitrilium ion (3). This reacts 
with carboxylate ion produced in the imine activation step to afford an imino-anhydride 
unstable (4), and lastly occurs the Mumm rearrangement (Image adapted from Tron, 
2013). 42 
 
Figure III.3: Tollens test of the agarose with aldehyde groups. The presence of a silver 
mirror or a black precipitate in the aldehyde- activated agarose revealed the presence of 
aldehyde groups. 45 
 
Figure III.4: Illustrative image of the 96-well filtration block used for the synthesis of the 
ligands based on Triazine reaction. From the top, with the order of addition of the 
compounds. R1 indicates the amines that were added to the second nucleophilic 
substitution and the R2 indicates the amines that were added to the last nucleophilic 
substitution used on the Triazine library. 47 
 
Figure III.5: Illustrative image of the 96-well filtration block used for the synthesis of the 
ligands based on Ugi reaction. From the top, with the order of addition of the compounds 
amine and acid carboxylic used in the Ugi library. 48 
 
Figure III.6: Structure from the protein PAB with the amino acids that bind to the domain 
II of HSA. Representation in ribbon model of the protein PAB (green), and the selected 
amino acids in stick (red) with the code, that were introduced for the synthesis of libraries. 
Image built in UCSF Chimera software (PDB code: 1GAB) (Lejon et al, 2004; Johansson et 
al, 1997). 50 
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Figure III.7: Screening results of Ugi reaction at pH 6.0. Screening was performed a loading 
pure HSA solution (250µg/ml) in PBS (10mM Sodium Phosphate, 150mM NaCl) at pH 6.0, 
to each well of a 96-well filtration block containing 0.25g of ligand-functionalized resin. The 
unbound protein from flow-through and washes was collected in 96-well transparent 
microplates and quantified by the QuantiPro
TM
 BCA method, measured at 560nm. (A) 
Amount in percentage of HSA bound in each ligand-functionalized support, using PBS at 
pH 6.0. (B) Schematic diagram representing the amount in percentage of HSA bound in 
each ligand-functionalized support, using PBS at pH 6.0. 55 
 
Figure III.8: Screening results of Ugi reaction at pH 7.4. Screening was performed a loading 
pure HSA solution (250µg/ml) in PBS (10mM Sodium Phosphate, 150mM NaCl) at pH 7.4, 
to each well of a 96-well filtration block containing 0.25g of ligand-functionalized resin. The 
unbound protein from flow-through and washes was collected in 96-well transparent 
microplates and quantified by the QuantiPro
TM
 BCA method, measured at 560nm. (A) 
Amount in percentage of HSA bound in each ligand-functionalized support, using PBS at 
pH 7.4. (B) Schematic diagram representing the amount in percentage of HSA bound in 
each ligand-functionalized support, using PBS at pH 7.4. 56 
 
Figure III.9: Screening results of Triazine reaction at pH 6.0. Screening was performed a 
loading pure HSA solution (250µg/ml) in PBS (10mM Sodium Phosphate, 150mM NaCl) at 
pH 6.0, to each well of a 96-well filtration block containing 0.25g of ligand-functionalized 
resin. The unbound protein from flow-through and washes was collected in 96-well 
transparent microplates and quantified by the QuantiPro
TM
 BCA method, measured at 
560nm.  (A) Amount in percentage of HSA bound in each ligand-functionalized support, 
using PBS at pH 6.0. (B) Schematic diagram representing the amount in percentage of 
HSA bound in each ligand-functionalized support, using PBS at pH 6.0. 57 
 
Figure III.10: Screening results of Triazine reaction at pH 7.4. Screening was performed a 
loading pure HSA solution (250µg/ml) in PBS (10mM Sodium Phosphate, 150mM NaCl) at 
pH 7.4, to each well of a 96-well filtration block containing 0.25g of ligand-functionalized 
resin. The unbound protein from flow-through and washes was collected in 96-well 
transparent microplates and quantified by the QuantiPro
TM
 BCA method, measured at 
560nm. (A) Amount in percentage of HSA bound in each ligand-functionalized support, 
using PBS at pH 7.4. (B) Schematic diagram representing the amount in percentage of 
HSA bound in each ligand-functionalized support, using PBS at pH 7.4. 58 
 
Figure IV.1: Screening results of putative Ugi ligands against IgG at pH 7.4. Screening was 
performed by adding a loading with pure IgG (250µg/ml) in PBS (10mM Sodium 
Phosphate, 150mM NaCl at pH 7.4), to each well of a 96-well filtration block containing 
0.25g of ligand-functionalized resin. The unbound protein from flow-through and washes 
was collected in 96-well transparent microplates and quantified by the QuantiPro
TM
 BCA 
method, measured at 560nm. (A) The 28 selected ligands that have more than 20% 
binding to HSA at pH 7.4, compared with the results obtained from the screening against 
IgG. (B) Enrichment factor of each selected ligand. 71 
 
Figure IV.2: Screening results of putative Triazine ligands against IgG at pH 7.4. Screening 
was performed by adding a loading with pure IgG (250µg/ml) in PBS (10mM Sodium 
Phosphate, 150mM NaCl at pH 7.4), to each well of a 96-well filtration block containing 
0.25g of ligand-functionalized resin. The unbound protein from flow-through and washes 
was collected in 96-well transparent microplates and quantified by the QuantiPro
TM
 BCA 
method, measured at 560nm. (A) The 23 selected ligands that have more than 50% 
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binding to HSA at pH 7.4, compared with the results obtained from the screening against 
IgG. (B) Enrichment factor of each selected ligand. 72 
 
Figure IV.3 : Screening results of the putative lead ligands of Ugi against HSA and IgG at 
pH 7.4 (n=3). Screenings were performed by adding a loading with pure HSA (250µg/ml) 
and pure IgG (250µg/ml) in PBS (10mM Sodium Phosphate, 150mM NaCl) at pH 7.4, to 
each well of a 96-well filtration block in triplicate containing 0.25g of ligand-functionalized 
resin. The unbound protein from flow-through and washes was collected in 96-well 
transparent microplates and quantified by the QuantiPro
TM
 BCA method, measured at 
560nm. (A) Percentage of HSA and IgG bound on each ligand. (B) Results of the 
Enrichment factor of each selected ligand (2
nd
 screening), and the previous results 
obtained (1
st
 screening). 73 
 
Figure IV.4: Screening results of the putative lead ligands of Triazine against HSA and 
IgG at pH 7.4 (n=3). Screenings were performed by adding a loading with pure HSA 
(250µg/ml) and pure IgG (250µg/ml) in PBS (10mM Sodium Phosphate, NaCl 150mM) at 
pH 7.4, to each well of a 96-well filtration block in triplicate containing 0.25g of ligand-
functionalized resin. The unbound protein from flow-through and washes was collected in 
96-well transparent microplates and quantified by the QuantiPro
TM
 BCA method, measured 
at 560nm. (A) Percentage of HSA and IgG bound on each ligand. (B) Results of the 
Enrichment factor of each selected ligand (2
nd
 screening), and the previous results 
obtained (1
st
 screening). 74 
Figure IV.5: Screening results of triazine lead ligands on-column (n=2).  Screenings were 
performed by adding a loading with pure HSA (250µg/ml) and pure IgG (250µg/ml) in PBS 
(10mM Sodium Phosphate, 150mM NaCl) at pH 7.4, to each column containing 0.5g of 
ligand-functionalized resin. The unbound protein from flow-through and washes was 
collected in 96-well transparent microplates and quantified by the QuantiPro
TM
 BCA 
method, measured at 560nm. (A) Amount in µg/g resin of HSA and IgG on-column (n=2) 
and in block of each lead ligand (n=3) (B) Percentage of HSA and IgG bound on-column 
(n=2) and in block (n=3) of each lead ligand. 75 
 
Figure IV.6: Elution results of triazine lead ligands. After screening, the HSA and IgG bound 
to ligand-functionalized supports were eluted by adding 0.5ml 0.1M Glycine- HCl at pH 2.5 
to each column. This procedure was performed 5 times. The eluted proteins were collected 
in 1.5ml tubes and after, it was necessary add 1M Tris -base at pH 9.0 to neutralize the 
samples. Posteriorly, the samples were analyzed in 96-well transparent microplate and 
quantified by the QuantiPro
TM 
BCA method, measured at 560nm. (A) Amount in μg/g resin 
of HSA and IgG eluted in each ligand. (B) Percentage of HSA and IgG eluted on each 
ligand. 77 
 
Figure IV.7: Lead ligands structure immobilized on agarose. The grey sphere is a 
schematic representation of an agarose bead. The structures were designed in 
MarvinSketch, ChemAxon. 78 
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I. Literature review  
 
 
This first chapter describes the unique properties and main applications of 
human serum albumin (HSA). There is a particular focus on natural and synthetic HSA 
binders and its applications.  
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1.1 Human serum albumin 
 
The human serum albumin (HSA) is a protein frequently found in plasma which is 
produced in the liver. The colloid osmotic pressure and the osmolality of the interstitial liquid 
around the hepatocytes are the major regulators of HSA biosynthesis (Fasano et al, 2005; 
Fanali et al, 2012). 
When an individual reaches a human plasma albumin concentration of 34- 54 g/l and 
with an average plasma volume of 2.5- 3.0L for a 70kg person, the average intravascular 
albumin mass is approximately 120g. HSA circulates from the blood across the capillary wall 
into the interstitial compartments and also cerebrospinal fluid, and returns to the blood through 
the lymphatic system with a circulation half-life of 16 days (Fanali et al, 2012). 
HSA is a component of many secretions from the human body including milk, sweat, 
tears and saliva, and is mainly degraded by intravascular space through larger organs, such as 
skin and muscles. The plasma HSA level decreases during periods of stress, trauma or sepsis 
despite its long half-life (Sleep et al, 2013). 
 
 
1.2 Structural and functional features of HSA and their natural binders  
 
1.2.1 Structural features 
 
 
The primary sequence of HSA shows that the protein is a single polypeptide with 585 
amino acids, having 17 pairs of disulfide bridges and one free cysteine at position 34 (Sugio et 
al, 1999). The disulphide bridges maintain the stability of HSA, explaining its relatively long 
biological half-life (Vusse, 2009). HSA has a single tryptophan residue at position 214. The 
methionine, glycine, and isoleucine residues are in low levels, whereas cysteine, leucine, 
glutamic acid, and lysine are in high levels. The large number of ionized residues gives to HSA 
a high total charge (i.e., 215 ions per molecule at pH 7.0), facilitating its solubility (Fanali et al, 
2012). 
 HSA is an α-helical, and a monomeric protein of 66kDa, composed by three 
structurally homologous domains (I, II, III) each being divided into two sub-domains (A, B) linked 
by random coil (Figure I.1) (Ghuman et al, 2005). The secondary structure of HSA is formed by 
α-helices (68%), without any β-sheet element. HSA has a globular heart-shaped form and each 
domain contains the following amino acids: I (1–195), II (196–383), and III (384–585). The three 
domains are comparable in the amino acid sequence as well as in the secondary and tertiary 
structure (Fanali et al, 2012). 
Each domain has ten helices (h), and is divided into antiparallel six-helix for the 
subdomain A and four-helix for the subdomain B. It was constituted by six (h1-h6) and four (h7-
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h10) α- helices, respectively, connected by an extended long loop (Varshney et al, 2010). To 
form the heart-shaped, the domain I and II are almost perpendicular to each other to constitute 
a T- shaped assembly in which the tail of subdomain IIA is attached to the interface region 
through the subdomains IA and IB by hydrophobic interactions and hydrogen bonds. In 
comparison, in an angle of 45°, the domain II overhang from subdomain IIB in a Y- shaped 
assembly for domains II and III. Domain III reacts only with subdomain IIB. The polypeptide 
chain folding and the disulfide bond topology are similar between the subdomains (Sugio et al, 
1999). As a result of the large number of acidic and basic residues, the structure of HSA 
undergoes reversible conformational transitions at different pH values (Fanali et al, 2012). 
 
 
 
Figure I.1 : Three-dimensional structure of human serum albumin. Representation in ribbon models of 
HSA determined in 1999 by X-ray crystallography with a high resolution (2.5Å) Structure of HSA with the 
subdomains in different colors (subdomain IA, in orange; subdomain IB, in yellow; subdomain IIA, in dark 
green; subdomain IIB, in light green; subdomain IIIA, in dark blue; subdomain IIIB in light blue). Image built 
in UCSF Chimera software (PDB code: 1AO6) (Sugio et al, 1999). 
 
Therefore, the structure of HSA changes when exposed to certain pH values: at pH 
lower than 2.7 it appears with an extended form; between pH 2.7 and 4.3 it appears in a fast-
migration form, defined by an increase in viscosity, much lower solubility, and the loss of α-helix 
with respect to physiological conditions (the neutral form). On the other hand, when exposed 
between pH 4.3 and 8.0, it displays the neutral form, characterized by the heart-shaped 
structure. But when exposed at pH greater than 8.0, HSA changes its conformation to the basic 
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form, characterized by the loss of α-helix and an increased affinity for some ligands, with 
respect to the neutral form (Fanali et al, 2012). 
 
 
1.2.2 Functional features 
 
 
HSA has an extraordinary ligand binding capacity, as a large and wide variety of 
compounds bind to it. Moreover, HSA turns potential toxins harmless by transporting them to 
the target sites; it is responsible for most of the antioxidant capacity of human serum (Bolli et al, 
2010). It is an important biomarker of many diseases, such as cancer, rheumatoid arthritis, and 
ischemia. Furthermore, HSA is largely used clinically to treat several diseases, like 
hypovolemia, shock, burns, trauma, hemorrhage, cardiopulmonary bypass, acute respiratory 
distress syndrome, acute liver failure, nutrition support and many others (Fanali et al, 2012). 
Currently, the biotechnological and biomedical applications of HSA include 
implantable biomaterials, surgical adhesives and sealants; as a reagent in affinity 
chromatography, and as a fusion partner of therapeutic proteins to increase the circulation half-
life (Fanali et al, 2012). 
The main physiological functions of HSA, recognized for over 70 years, are the control 
of osmotic pressure and capillary membrane permeability and the ability of ligand binding and 
transport of many compounds (Fanali et al, 2012). 
As an excellent carrier, HSA is involved in the transport of nutrients such as non-
esterified fatty acids; heme group; lipophilic xenobiotics; hormones, such as thyroxine; amino 
acids; bile acids; steroids and it is also capable of transporting a wide range of therapeutic 
substances, through the bloodstream (Lexa and Jacobson, 2014; Curry, 2009; Lejon, 2004). In 
addition, it also binds a wide variety of drugs, being an important factor in the pharmacokinetic 
procedure, affecting their efficacy and rate of delivery. HSA is also related with the antioxidant 
capacity of human serum, by binding and transporting radical scavengers, or by sequestering 
transition metal ions with pro-oxidant activity (Fasano et al, 2005).  
 
 
1.2.3 Ligand binding properties 
 
 
HSA is well known for its excellent ligand binding capacity, due to its capacity to work 
as a reservoir for a great variety of compounds that may be available in quantities well beyond 
their solubility in plasma (Fasano et al, 2005). The tertiary structure of albumin, allows it to bind 
and transport a wide variety of molecules, such as metabolites (e.g., cholesterol, fatty acids, 
cations, and anions), gases (e.g., NO), exogenous substances (e.g.,Drugs) (Table I.1) (Fanali et 
al, 2012; Bolli, 2010). Although many ligands for HSA are hydrophobic or anionic, there are also 
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heavy metals and few cationic drugs also known to bind to HSA. This variability arises from the 
presence of multiple binding sites, which are dependent on many environmental factors like pH, 
temperature and ionic strength (Varshney et al, 2010). 
It has the ability to bind many small molecules with micromolar affinity, and to control 
the outcome of certain chemical reactions. The broad binding action and chemical reactivity are 
related with the binding site located in the HSA subdomain IIA, also known as the Sudlow site I 
(Drug site I) (Luisi et al, 2013). 
Other proteins can also interact with HSA, as part of its daily round through the 
circulation, to increase its half-life time. In addition, HSA has a size above the renal filtration 
cutoff and a pH-dependent binding to the neonatal Fc receptor (FcRn), which offers a rescue 
mechanism to avoid HSA and immunoglobulin G (IgG) degradation through the lysosomal 
degradation pathway (Nilvebrant and Hober, 2013). 
Through a study of Ghuman and co-workers in 2005, it was possible to obtain several 
three-dimensional structures of HSA with many ligands and its specific binding sites (Figure I.2). 
In this study, the authors used drugs with acidic or electronegative features (e.g. warfarin, 
diazepam, ibuprofen and azapropazone) to test the binding to HSA. It was demonstrated that 
normally they bind at one of two primary sites (1 and 2), located in subdomains IIA and IIIA, 
respectively (Figure I.2) (Ghuman et al, 2005). 
HSA can bind seven equivalents of long-chain fatty acids (FAs) at many binding sites 
with different affinities. In this case of FA1 to FA5 represented in the Figure I.2, the carboxylate 
part of fatty acids is anchored by electrostatic/polar interactions. On the other hand, sites FA6 
and FA7 do not show a clear evidence of polar interactions that keep in place the carboxylate 
head of the fatty acid, thus suggesting that sites FA6 and FA7 have a lower affinity with the FA 
binding sites (Fasano et al, 2005). 
When HSA is at physiological conditions, it binds not only endogenous and exogenous 
low molecular weight compounds but also peptides and proteins. There are thirty-five proteins 
that bind to HSA including high and low molecular weight proteins (e.g., angiotensinogen, 
apolipoproteins, ceruloplasmin, clusterin, hemoglobin (Hb), plasminogen, prothrombin, and 
transferrin). Any binding of proteins and peptides to HSA leads to proteomics and biomarker 
discovery studies, as the presence of both unbound and bound states of proteins in serum can 
change both the clearance and the detection of the free-state proteins and peptides (Fanali et 
al, 2012).  
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Table I.1: List of exogenous and endogenous molecules that bind to HSA and its respective binding site. 
 Molecules HSA binding site References 
Endogenous 
Fatty acids (e.g., Myristic 
acid, Oleic acid and 
Decanoic acid) 
FA1 (Subdomains IB 
and IIA), FA2 and FA3 
(Subdomain IIIA), FA5 
(Subdomains IIIB and 
IIIA), FA6 and FA7 
(Subdomains IIA and 
IIIA). 
Fasano et al, 2005; 
Petitpas et al, 2001; 
Bhattacharya et al, 
2000 
Hormones (e.g., 
Thyroxine) 
Subdomains IIA, IIIA 
and IIIB 
Fanali et al, 2012 
Metal ions (e.g., Nickel 
(II) and Mercury (II)) 
N-terminal binding site 
(Aspargine 1, Alanine 2 
and Histidine 3) and 
Free Cysteine 34 thiol 
Fanali et al, 2012 
Bilirrubin Subdomain IB Fanali et al, 2012 
Vitamins (e.g., B12) N/A Hou et al, 2008 
Cholesterol N/A Fanali et al, 2012 
Exogenous 
Benzodiazepines drugs 
(e.g., Diazepam) 
Subdomain IIIA (Drug 
site 2) 
Ghuman et al, 2005 
Anti-inflammatory drugs 
(e.g., Ibuprofen) 
Subdomain IIA, IIB and 
IIIA (Drug site 2) 
Ghuman et al, 2005 
Anticoagulant drugs (e.g, 
Warfarin) 
Subdomain IIA (Drug 
site 1) 
Ghuman et al, 2005 
Anesthetic drug (e.g., 
Propofol) 
Subdomain IIIA (Drug 
site 2) and IIIB 
Ghuman et al, 2005 
Antibiotic drug (e.g., 
Daunomycin) 
N/A Tang et al, 2005 
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Figure I.2: Structure of HSA with ligand binding sites. Representation in ribbon models of HSA with 
myristic acid and azapropazone determined in 2005 by X-ray crystallography with a high resolution (2.5 Å). 
The six subdomains of HSA are colored as follows: subdomain IA: orange; subdomain IB: yellow; 
subdomain IIA: dark green; subdomain IIB: light green; subdomain IIIA: dark blue; subdomain IIIB: light 
blue. The drug site II is occupied by myristic acid (fatty acid) and the drug site II is occupied by 
azapropazone (drug), both white. Oxygen atoms are colored red and nitrogen atoms blue. Image built in 
UCSF Chimera software (PDB code: 2BXI) (Ghuman et al, 2005). 
 
 
 Human FcRn binding 1.2.3.1
 
 
The neonatal Fc receptor (FcRn) develops a central role in the regulation of IgG and 
serum albumin (SA) in mammals. FcRn is a 52kDa heterodimer, has a MHC (major 
histocompatibility complex) class I- related receptor consisting a heavy chain, which is non- 
covalently associated with β2-microglobulin (B2M) light chain (Figure I.3) (Mezo et al, 2010). 
FcRn may bind IgG and albumin simultaneously, and in a pH-dependent manner, with ligand 
binding at pH 6.0 and release at pH 7.4 (Oganesyan et al, 2014; Andersen et al, 2006). 
The conjugation of proteins or peptides that have poor bioavailability or exhibit rapid 
clearance to the FcRn ligands (IgG, Fc molecule and albumin) can increase their 
pharmacokinetics owing to FcRn- mediated recycling and transport, and thereby obtaining 
greater therapeutic effects  (Kontermann, 2012). 
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Figure I.3: Three-dimensional structure of the human neonatal Fc receptor. Representation in ribbon 
models of the human neonatal Fc receptor determined in 2010 by X-ray crystallography with a high 
resolution (2.6 Å). The red is the heavy chain called IgG receptor, and the light chain β2- microglobulin in 
orange. Image built in UCSF Chimera software (PDB code: 3M1B) (Mezo et al, 2010). 
 
 
 
Binding to HSA has been shown to extend the in vivo half-life of proteins, and is 
known to have great potential as strategy for increasing the potency of biological drugs, through 
a mechanism which depends on the binding of HSA to FcRn at acidic pH in the endosomes 
(Nilvebrant et al, 2011). Endocytosis process allows the transport of substances through the 
extracellular space to the intracellular by endocytic vesicles, and many times, these substances 
are sorted to the lysosome and are degraded (Figure I.4) (Schmidt et al, 2013). 
A study demonstrated that the concentration of albumin was approximately 40% lower 
in FcRn heavy chain deficient mice compared with normal mice. In addition, the data indicate 
that the capacity of FcRn is extraordinary, as albumin is degraded twice as fast in FcRn-
deficient mice as in the wild type strain and almost four times more IgG is saved from 
degradation than is produced by the mouse (Andersen et al, 2006; Kim et al, 2006). 
Oganesyan and colleagues, in 2014, indicate that the residue histidine 161 is the only 
potential direct contributor to the corresponding pH-dependent process (Figure I.5) (Oganesyan 
et al, 2014). However, a study by Sand and co-workers, in 2014, demonstrated that not only DIII 
but also DI of albumin is important for optimal pH-dependent binding to FcRn (Sand et al, 2014). 
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Figure I.4: FcRn mediated pH- dependent, recycling and transport of IgG and HSA. Plasma proteins 
are pinocytosed along with a variety of other constituents at neutral pH (pH 7.4) (light blue shading), then 
move to the acidic endosomal (pH 6.0) (pink shading) compartments where IgG (structure in dark blue) 
and albumin (structure in red) bind to FcRn receptor (structure in green) with high affinity at distinct binding 
sites. Unbound plasma proteins (purple lozenge shaped) or excess ligands, when FcRn is satured, are 
destined for degradation in lysosomes (circle in grey), while bound complex is sent to the cell membrane 
where IgG and albumin dissociate from FcRn at physiological pH, providing a longer survival for the two 
proteins. Image built in UCSF Chimera software (PDB code: 3M1B, 1AO6 and 1IGT) (Image adapted from 
Kontermann, 2012).  
 
Figure I.5: Structure of human FcRn complexed with HSA. Representation in ribbon models of the 
human FcRn complexed with HSA determined in 2014 by X-ray crystallography with a high resolution (3.0 
Å). (A) FcRn receptor with receptor IgG heavy chain bound mainly to the domain III of HSA. (B) Detail on 
the residue histidine 161 (grey) from FcRn, contributor to the pH-dependent process. Image built in UCSF 
Chimera software (PDB code: 4N0F) (Oganesyan et al, 2014). 
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1.3 Applications HSA 
 
 
The average HSA consumption in the developed world is 200-400 kg/million 
inhabitants. Annually in the industry of therapeutic protein manufacture, more than 500 metric 
tons of HSA and more than 40 tons of intravenous immunoglobulins (IVIG) are produced from 
more than 22 million liters of source and recovered plasma, reaching up to 34 million liters. This 
$6.9 billion industry supplies products to more than one million inhabitants each year (Curling, 
2004).  
In the biomedical applications, HSA can be found in three different ways, such as HSA 
alone, HSA fused with biological proteins/peptides or HSA complexes, being of much interest in 
the therapeutic area (Table I.2). 
 
Table I.2: List three different forms with HSA can be found in biomedical applications. HSA  structure in 
red. Image built in UCSF Chimera software (PDB code: 1AO6). 
 HSA Form Application Source References 
 
 
 
HSA/rHSA 
Treatment form 
and biomarker 
of many 
diseases 
Blood 
fractionation/ 
Genetic 
Engineering 
Burnouf, 
2007; Wilkes 
and Navickis, 
2001; 
Chuang and 
Otagiri, 2007 
 
 
 
HSA fusion 
with 
biological 
proteins/ 
peptides 
Increase the 
half-life of 
biodrug 
 
Protein 
engineering 
Kontermann, 
2009; 
Elsadek and 
Kratz, 2012 
 
 
 
HSA 
complexes 
Improving the 
pharmacokinetic 
properties of the 
(bio)drugs 
 
Protein 
engineering 
& 
development 
of HSA 
binders 
Elsadek and 
Kratz, 2012 
 
 
For a long time, HSA is emerging in the pharmaceutical industry due to its ability to 
bind a wide range of drug molecules and modify its pharmacokinetic parameters, contributing 
for the treatment of several chronic and acute diseases (Gundry et al, 2007; Grazzini et al, 
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2013; Varshney et al, 2010). Protein products fractionated from human plasma are widely used 
for therapeutic purposes, often as the only available option to the prevention, management, and 
treatment of severe diseases (Burnouf, 2007). Albumin administration is an alternative of 
treatment of many diseases as hypovolemia and shock; burns; hypoalbuminemia and 
hypoproteinemia; surgery; traumas; cardiopulmonary bypass; the acute nephrosis; 
hyperbilirubinemia; acute liver failure; ascites; and sequestration of protein-rich fluids in acute 
peritonitis, pancreatitis, mediastinitis, and extensive cellulitis (Wilkes and Navickis 2001). 
HSA is emerging as a portable protein carrier for drug targeting and for improving the 
pharmacokinetic profile of peptide or protein-based drugs. Drugs, prodrugs or polypeptides can 
either be bound physically or covalently through a ligand or protein-binding group to HSA. More 
complex systems are known to have the attachment with numerous targeting ligands and 
prodrugs bound to the protein surface or nanobodies or bispecific antibodies that bind physically 
or are fused with albumin replacing the Fc fragment of immunoglobulin G (Elsadek and Kratz, 
2012). 
Many studies with direct fusion to whole albumin have been applied to a variety of 
proteins, such as interferons, IL-2 (Interleukin-2), insulin, human growth hormone, and antibody 
fragments. These proteins were fused to either the N- or C-terminus of HSA (Kontermann, 
2009). A study in vitro used the thioredoxin (Trx), a redox-active protein, fused to HSA, resulting 
in about 40% reduction in the Trx biological activity. However the HSA–Trx fusion protein has 
proven to be therapeutically effective in the septic shock mouse model, because the HSA–Trx 
had higher distribution in the lungs than in other organs, as well as 10 times longer plasma half-
life than Trx in normal mice (Furukawa et al, 2011).  
 
 
1.4 HSA binders 
 
 
Binders to HSA can find several applications, namely: 
 
 The binder can capture HSA and be used for HSA depletion or purification 
 The binder can be employed to detect HSA in vivo or in vitro for diagnostic 
purposes when HSA can be considered a biomarker;  
 The binder can be covalently linked to a drug or biodrug and, once bound to 
HSA, be used to increase the half-life of the therapeutic agent. 
 
1.4.1 Natural HSA binders 
 
Many Gram-positive bacterial species, including human pathogens, express surface 
proteins that interact with host proteins like HSA and IgG with high specificity and affinity 
(Ascenzi et al, 2006). The surface proteins typically contain tandemly repeated serum protein-
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binding domains with one or many specificities, which often include albumin binding (Nilvebrant 
and Hober, 2013). 
The bacterial species that express albumin-binding domains (ABDs) are normally part 
of the normal human flora and they are opportunistic pathogens. There are several types of 
albumin-binding proteins with different sizes and functions (Nilvebrant and Hober, 2013; 
Jonsson et al, 2008). Examples of bacterial proteins that bind to HSA are protein G (Jonsson et 
al, 2008), protein PAB (Lejon et al, 2004), protein MAG (Jonsson et al, 1994), protein ZAG 
(Jonsson et al, 1995) and protein H (Frick et al, 1994) (Table I.3). The binding strength between 
different ABDs and serum albumin from different species can vary widely, which has been 
investigated in many studies (Jonsson et al, 2008). The fact that most of the ABDs recognize 
the domain II of HSA, having no overlap with the binding site of the FcRn receptor, is of greatest 
importance for the control of HSA homeostasis (Nilvebrant and Hober, 2013). 
 
 
Table I.3: List of the most known protein with albumin binding domains (ABDs). Aas- Amino acid residues. 
 
ABD Organism Size (Aas) Reference 
Protein G 
Group C or G 
Streptococcal  
46  Jonsson et al, 2008 
Protein PAB 
Peptostreptococcus 
magnus 
45  Lejon et al, 2004 
Protein MAG 
Streptococcus 
dysgalactiae 
60  Jonsson et al, 1994 
Protein ZAG 
Streptococcus 
zooepidemicus 
52  Jonsson et al, 1995 
Protein H 
Streptococcus 
pyogenes 
112  Frick et al, 1994 
 
 
 
 
Proteins with ability to bind serum albumin, including ABDs, peptides or antiserum 
albumin antibodies, have been used in several important applications within biotechnology and 
biotherapy (Jonsson et al, 2008).  
 
 
  Protein G 1.4.1.1
 
 
Over the past 30 years, different streptococcal species, which bind to HSA with high 
affinity, have been identified (Egesten et al, 2011). 
Protein G is expressed at the cell surface of certain group C and group G 
streptococcal strains, and it is known to be a bi-functional receptor, because it binds to IgG and 
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HSA in different regions. These regions have three independently folded domains (Figure I.6) 
(Sjöbring, 1992; Björck et al, 1987). 
The ABD, also known as GA module, is at the N-terminal region, and the binding 
region to IgG is in the C domain of the C-terminal region (Egesten et al, 2011). 
 
 
 
Figure I.6: An overview of the streptococcal protein G (SpG). The HSA and Imunoglobulin Binding 
sites are in different domainsof the protein. However, both have three homologous domains. Nomenclature 
according to Ståhl and Nygren (1999) (adapted from Linhult et al, 2002). 
 
The three homologous HSA-binding domains from protein G have similar sequences 
and are called ABD1, ABD2, and ABD3. Through a study of Johansson and co-workers in 2002, 
it was possible to obtain the structure of ABD3 from protein G (strain G148) by Nuclear 
magnetic resonance (NMR) spectroscopy, (Figure I.7), which showed to have a left-handed 
three-helix bundle structure (Johansson et al, 2002). It consists of 46 amino acids and it is 
stable enough to be independent from disulfide bridges, does not require ligands, cross-linkers 
or metal ions for folding (Linhult et al, 2002). HSA contains one binding site for protein G, 
formed by loops 6–8 of HSA. This region also contains the binding sites for tryptophan, fatty 
acids, and thyroxine (Johansson et al, 2002). 
The ABD has an excellent chemical and thermal stability, and therefore, is a suitable 
scaffold for protein engineering (Linhult et al, 2002). The amino acids from protein G responsible 
for most part of affinity with HSA were identified by alanine- scanning procedure, followed by 
binding studies using different methodologies- surface plasmon resonance (SPR), circular 
dichroism (CD) and affinity blotting. Most of these amino acids are located in the second helix. 
Moreover, it was possible to conclude that helix 1 and also most part of helix 3 are probably not 
involved in the binding to HSA (Linhult et al, 2002). 
As an alternative to direct fusion to HSA, many molecules have been exploited as 
albumin-binding moieties, doing reversible, non-covalent interaction with HSA. Several in vivo 
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studies demonstrated the applicability of fusion to the ABD from protein G to increase the 
plasma half-lives of small antibody molecules (e.g. Fragment antigen-binding (Fab), biospecific 
antibody derivatives) and several antibody mimetics. Fusion of the ABD to the C-terminus of the 
light chain of an anti-HER2 Fab increased the terminal half-life in mice from approximately 2 
hours to 20.9 hours. However, there are concerns due from the fact that this ABD is derived 
from a bacterial protein, which has been shown to be immunogenic. Impressively, it was shown 
that the ABD from protein G is capable of reducing the immunogenicity of a fusion partner, and 
that fusion proteins containing ABD may be administered repeatedly, without raising an immune 
response (Kontermann, 2009; Schlapschy et al, 2007). 
 
 
Figure I.7: Three-dimensional structure of albumin binding domain from Protein G. The structure 
was determined by NMR spectroscopy in 2002. ABD structure with three-helix bundle. The helices 2 and 3 
are red with the code of the respective amino acids, site of highest affinity to HSA. Image built in UCSF 
Chimera software (PDB code: 1GJS) (Johansson et al, 2002).  
 
Other studies have demonstrated that the non-covalent association with HSA has 
been useful to extend the half-life of short lived proteins. In an in vivo study, the recombinant 
fusion of the ABD from streptococcal protein G to human complement receptor type 1 was 
performed. Using this fusion protein, it was possible to increase its half-life 3-fold, for 5 hours in 
rats. Furthermore, fusion to this domain has served to enhance the immunological response 
directed to peptide antigens (Dennis et al, 2002; Makrides et al, 1996). 
 
 
  Protein PAB 1.4.1.2
 
 
The protein PAB (peptostreptococcal albumin-binding), is expressed at the surface of 
the Gram-positive anaerobic bacterium Peptostreoptococcus magnus, present in the indigenous 
flora of the skin, oral cavity, and the gastrointestinal and urogenital tracts (Lejon et al, 2004).  
The protein PAB contains a domain for binding to HSA named after the GA (protein G-related 
albumin-binding) module. This contains 45 residues, is composed by a left-handed three-helix 
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bundle, being therefore structurally and functionally similar to ABD from protein G (Figure I.8) 
(Johansson et al, 1997).  It was postulated that the conserved region in the C-terminal part of 
the second helix and the flexible sequence between helices 2 and 3 could contribute to the 
albumin-binding activity (Lejon et al, 2008; Johansson et al, 2002). The GA module has a fold 
that is impressively similar to the immunoglobulin-binding domains of staphylococcal protein A, 
but it is not similar to the fold shared by the immunoglobulin-binding domains of streptococcal 
protein G and peptostreptococcal protein L (Johansson et al ,1997). 
 
 
 
 
Figure I.8: Structure of the albumin-binding GA module. The structure was determined by NMR 
spectroscopy in 1997. Three- dimensional structure of GA module with the helix 1 in green and the helices 
2 and 3 are red with the code of the respective amino acids, site of highest affinity to HSA. Image built in 
UCSF Chimera software (PDB code: 1GAB) (Johansson et al, 1997). 
 
According to the study of Lejon and co-workers, in 2004, the GA module residues from 
the second helix and the two loops surrounding, bind to HSA in the domain II. More precisely, 
they bind in the helices 2 and 3 of domain IIA and in the helices 7 and 8 of domain IIB, close to 
a cleft bounded by helices 2 and 3 (Figure I.9). Residues phenylalanine 27, alanine 31, leucine 
44, isoleucine 48, threonine 24, serine 25, tyrosine 28, threonine 37 from GA participates in the 
binding to HSA. The presence of fatty acid in the HSA-GA binding interface might influence the 
complex formation (Lejon et al, 2004). Based on previous observations of fatty acid-induced 
conformational changes in HSA, it is possible that the difference in global conformation of the 
albumin chain in the two structures of the HSA–GA complex is caused by the difference in fatty-
acid content (Lejon et al, 2008). 
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Figure I.9: Structure of the GA module complexed with HSA. Representation in ribbon models of HSA 
determined in 2004 by X-ray crystallography with a high resolution (2.7 Å).  (A) The GA module binds in 
the domain II of HSA. The HSA molecule is shown in blue and the GA module in red. (B) Detail in the 
interactions between HSA side chains and the GA helices (red) pack at almost right angles to helices 3, 4, 
and 7 (h3, h4, and h7) in HSA domain II. Image built in UCSF Chimera software (PDB code: 1TF0) (Lejon 
et al ,2004).  
 
A study by Johansson and co-workers, in 2002, through a comparison of the G148-
GA3 protein (protein G) with ALB8-GA protein (protein PAB) demonstrate that both bind HSA. 
Both domains share 59% sequence identity and bind to the same site. However, the specificity 
of G148-ABD is much broader than for ALB8-GA, despite that the binding affinity of ALB8-GA 
for HSA is roughly two fold higher. In addition, streptococci expressing G148-ABD have much 
broader host specificity and this domain binds albumin from several non-primates better than 
ALB8-GA. As would be expected, competitive binding studies have shown that G148-ABD and 
ALB8-GA have the same binding site on HSA (Johansson et al, 2002). 
 
1.4.2 Synthetic binders 
 
 
Through of the progresses in molecular modeling, genetic engineering and both 
natural and synthetic combinatorial methodologies, have made possible the design and 
development of engineered of peptides and engineered protein domains and fully synthetic 
molecules (Roque et al, 2007). 
The purification of HSA has attracted considerable attention in the pharmaceutical 
industry by its great binding potential. The biomimetic dye-ligands (e.g., triazine dyes) offer 
DII 
DI DIII 
17 
 
many advantages as its low cost, ease of immobilization, stability and high adsorption capacity 
(Kassab et al, 2000). 
Albumin-binding peptides (ABP) also represent an alternative to the use of bacterial 
ABDs, with the advantage of the smaller size. Such ABPs have been isolated from random 
peptide libraries applying phage and bacterial display, but were found to present a low affinity to 
HSA. The association, conjugation or fusion of therapeutic drugs to albumin is a well-accepted 
and established half-life extension methodology. The manipulation of the albumin–FcRn 
interaction will facilitate the modulation of the circulatory half-life of albumin-enabled drugs, 
leading to improve in the pharmacokinetics (Sleep et al, 2013). 
Dennis and co-workers at Genentech Inc., in 2002, published a work on the 
attachment of albumin-binding single chain antibodies. They found a peptide with 18 amino 
acids (Ac-RLIEDICLPRWGCLWEDD-NH2) with high binding affinity for HSA (Kd~0.5μM). A 
related sequence QRLMEDICLPRWGCLWEDDF comprising 20 amino acids was then fused 
with a single chain antibody D3H44 Fab directed against the tissue factor and showed a similar 
affinity for HSA. This fusion protein was then injected in mice and rabbits and it was observed 
an increased in the plasma half-life 26-fold to 10.4 hours and 37-fold to 32.4 hours, respectively. 
These results demonstrated a 25–43% increase in the half-life in these animals. Thus, by 
attachment of a small peptide to a single chain antibody the rapid clearance of the native single 
chain antibody, that normally limits their therapeutic usefulness, could be overcome and can 
deeply affect its pharmacokinetic profile (Dennis et al, 2002). 
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1.5 Aims of the work 
 
HSA besides being an important versatile carrier protein in plasma, can also is used 
clinically for the treatment of many diseases (e.g., hypovolemia, shock and burns) and as a 
biomarker for cancer, rheumatoid arthritis, and ischemia.  
For this reason, the development of ligands with affinity for HSA may be an effective 
strategy for improving the pharmacokinetic properties of drugs or biodrugs and also for HSA 
purification, which posteriorly can be used for clinical purposes. Within this context, the aim of 
this research project is the development of biological and synthetic affinity ligands towards HSA 
(Figure I.10). 
 
 
 
Figure I.10: Schematic representation of the procedures performed in this study.  Image for the 
structures of the protein PAB and IgG were built in UCSF Chimera software (PDB code: 1AO6, 1GAB and 
1IGT).  
 
The first approach was to optimize the expression of a biological ligand, a small 
protein domain previously selected by phage display to present affinity towards HSA. This 
ligand is of biological origin, and therefore, has low toxicity and having a small size can be 
synthesized biologically and chemically. 
In the second approach, the aim is to develop synthetic ligands with affinity to HSA, 
based on combinatorial chemistry to produce solid-phase libraries of ligands. These ligands are 
more resistant and are more easily produced. They can be used for the purification of HSA, or 
19 
 
to increase the half-life of drugs and therapeutic proteins when in complex with HSA. However, 
in this work was explored only the purification of HSA. 
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II. Optimization of the expression of and 
engineered biological ligand for 
human serum albumin 
 
 
The aim of this chapter was to express the WW Clone 3 protein in E. coli strain BL21 
(DE3) using pET expression vector system and test its affinity towards HSA to confirm the 
results obtained from the panning of the phase display library.  From previous work in the 
laboratory, it was verified that the expression of this family of proteins without a partner protein 
(co- expression) was difficult. 
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2.1 Introduction 
 
Biological ligands are biomolecules derived from natural sources and from in vitro 
selection techniques, as phage, ribosome or cell free display techniques. These are usually 
associated with high selectivity and affinity for the target (Pina et al, 2014b).  
Protein domains are natural modulators of biological function through ligand binding. 
These domains can be modified in order to produce altered activities or binding specificities and 
create novel affinity reagents. Usually, engineering efforts focus upon modification or 
randomization of the loops in globular structures (Patel et al. 2013). 
WW domains are a family of protein-protein interaction modules that are found in 
many eukaryotes and are present in approximately 200 human proteins. This small domain 
contains two conserved tryptophan residues, which justifies the name WW domain.  The WW 
domains are sometimes present in multiple copies in a protein (for example, in Rsp5/Nedd4 or 
in the mouse YAP65) (Staub and Rotin, 1996; Ingham et al, 2005). While the WW domain was 
initially considered a 'cytoplasmic module', the proteins that have WW domains were also 
localized in the cell nucleus (Sudol et al, 2001).  
 WW domains are typically 35 to 40 amino acids in length and fold into a three-
stranded antiparallel β- sheet with two ligand-binding grooves, while in the region between the 
N- terminus and C-terminus there are hydrophobic interactions (Ingham et al, 2005; Macias et 
al, 2000). This protein is one of the smallest protein module that folds as a monomer without 
disulfide bridges or cofactors. Moreover, this domain binds proteins containing short linear 
peptide motifs that are proline-rich or contain at least one proline. Through the recognition of 
proline-rich regions, the WW domain has a role in mediating protein-protein interactions (Sudol 
et al, 2001; Chen and Sudol, 1995). 
Macias and colleagues, in 2000, designed a WW domain sequence designated as a 
WW prototype. This sequence was designed based on the analysis of amino acid distribution in 
the WW domain sequences and on the network of conserved contacts, and this structure 
satisfies the structural requirements of the typical WW domain folding. This showed how a 
small, independently folding unit can accommodate a high degree of sequence variability 
without altering its basic three-dimensional structure. Furthermore, the WW fold may constitute 
a template into which binding sites from unrelated proteins may be used as a strategy to 
develop proteins with novel properties (Macias et al, 2000).  
Previously in our Research Group, a template sequence based on the WW prototype 
has been developed for in vitro selective, against HSA by phage display. The best binder 
selected was named WW Clone 3, and differs from the WW prototype because it possesses 
larger loops. The WW Clone 3 has five amino acids in loop I, and four amino acids in loop II. 
The WW Clone 3 is a protein with approximately 160bp (5kDa), and has a very hydrophobic 
character (Figure II.1). 
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Figure II.1: Structure of the WW Clone 3. (A) Structure of the WW prototype (blue), with three-stranded 
antiparallel β- sheet, and the amino acids proline and tryptophan are in yellow and green, respectively. (B) 
Structure of the WW Clone 3 (red) based on WW prototype. The loops were randomized. In the loop I, 
three amino acids were added and in the loop II, two amino acids were added. (C) The structure of WW 
prototype (blue) and the WW Clone 3 (red) overlapped. The loops from WW Clone 3 are increased 
compared to the WW prototype. (D) Protein Sequence of WW Clone 3 has five amino acids in loop I, and 
four amino acids in loop II. Images built in UCSF Chimera software, the structure of the WW prototype with 
PDB code: 1E0M (Macias et al, 2000). 
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2.2 Material and methods 
 
2.2.1  Materials 
 
Vector pEX WW Clone 3 was purchased from Eurofins (Germany) and the pET 21c 
expression vector kindly provided by Dr. Ana Pina (DQ, FCT, UNL).  
The Top10 F‟ and BL21 (DE3) electro competent cells from E. coli were kindly 
provided by the group of Prof. Dr. João Gonçalves (Pharmacy Faculty, University of Lisbon, 
Portugal).  
The restriction enzymes for modification of plasmid DNA were: NheI and BamHI 
FastDigest and the enzyme FastAP Thermosensitive Alkaline Phosphatase which were 
purchased from Thermo Scientific (Portugal). The DNase I was purchased from Roche 
(Germany).  
Bovine Serum Albumin (BSA) and the Bicinchoninic Acid (BCA) Kit were acquired 
from Sigma- Aldrich (Portugal).  
For DNA (Deoxyribonucleic acid) purification the NZY Gelpure kit was used, and for 
the preparation of pure plasmid DNA from recombinant E. coli strains the Miniprep kit was used, 
both acquired from NzyTech (Portugal).  
The Luria broth (LB) medium, ampicillin antibiotic, T4 DNA ligase, Isopropyl-beta-D-
thiogalactopyranoside (IPTG), Agarose (ultrapure grade), N,N,N,N,Tetramethylethylenediamine 
(TEMED) were purchased from NzyTech (Portugal). The Agar was purchased from HIMEDIA 
(Portugal).  
For the DNA electrophoresis, the DNA markers used were NzyTech Ladder III and V, 
loading dye, Greensafe premium, purchased from NzyTech (Portugal). The Precision Plus 
Protein
TM
 dual color standards was purchased from Bio- Rad (Portugal). For the Protein 
electrophoresis the ammonium persulphate (APS) was employed.  
For the Western Blotting method, the Immobilon-P
SQ
 Membrane (0.2µm) was used 
and acquired from Merck Millipore (Germany). Tween 20, Coomassie Brilliant Blue R, β- 
mercaptoethanol were purchased from Sigma (Portugal). The Mini-PROTEAN Tris 
(Tris(hydroxymethyl)aminomethane )-Tricine precast gel and Acrylamide – Bis acrylamide 30:8 
were purchased from Bio- Rad (Portugal). The Step
TM
 TMB- Blotthing was acquired from 
ThermoScientific (Portugal). The Penta His HRP Conjugate Kit with Blocking Buffer were 
purchased from Qiagen (Portugal).  
 
2.2.2 Equipment 
 
Standard laboratory equipment were needed, including: Vortex mixer VX-200 Labnet 
International Inc., Micro centrifuge- ScanSpeed, Micro Centrifuge Frilabo, Incubator ZKA 
KS4000i control, Centrifuge Thermo (Bio-Rad T100
TM
 Thermal Cycler), Spectrophotometer 
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Ultraspec 2100, Microplate reader TECAN Infinite F200, FrechPress and Nanodrop 1000 from 
Thermo Scientific (Portugal). Ultracentrifuge optima LE80K (Rotor type 45 Ti) from Beckman 
Coulter. To obtain the image of the gel, the GelDoc from Bio- Rad (Portugal) was employed. It 
was used software Chimera to obtain the image of the proteins structures. 
 
2.2.3  Buffers  
 
The following buffers and reagents were used: Tris (Tris-(hydroxymethyl) 
aminomethane) Acetate- EDTA (TAE) 50x (2M Tris- base, 1M Glacial acetic acid, 0,1M 
Ethylenediaminetetraacetic Acid (EDTA) at pH 8.5) from which was prepared TAE 1x; Tris- 
Tricine 10x (1M Tris, 1M Tricine, 1% Sodium dodecyl sulfate (SDS), pH 8.3) and was used in 
Tris- Tricine 1x; Phosphate buffered Saline buffer (PBS) (10mM Sodium phosphate, 150mM 
Sodium Chloride (NaCl), at pH 7.4) and was also used PBS with 0.05% Tween 20; Transfer 
Buffer (25mM Tris- Base, 195mM Glycine, 40% Methanol); Tris- Buffered Saline (TBS) 1x 
(50mM Tris- Base and 150mM NaCl, pH 7.5) and was also used TBS with 0.1% Tween 20; 
Coomassie Blue R-250 (0.1% Coomassie Blue R-250, 0.15% Glacial acetic acid, 0.9% 
Methanol); Tris- Glycine buffer (0.25M Tris-base, 1.92M Glicine, SDS, pH 8.3); Concentration of 
the gel Buffer II (0.5M Tris-base, 0.125M Tris-HCl (Hydrochloric acid), pH 6.8); Separating gel 
Buffer I (3M Tris-base, 0.375M Tris- HCl, pH 8.8); 10% APS, IPTG 1M stock 238.3g/mol; LB 
medium liquid (LB medium 25g/l in Milli-Q water) and LB medium solid (1.5% Agar in LB 
medium 25g/l in Milli-Q water), SOC (Super Optimal broth with Catabolite repression) medium 
(31.54g/l in Milli-Q water). 
 
2.2.4 Methods 
 
 
 Cloning strategy 2.2.4.1
 
For expression of the protein WW Clone 3, it was necessary to first clone the gene 
codifying the protein of interest into the vector expression vector. As expression vector we 
selected a pET system (vector pET 21c, Ampicillin Resistance (Amp
R
) for expression in E. coli 
BL21 (DE3). The gene codifying the protein was in a transporter vector pEX (Eurofins). These 
vectors have two sequences which are specifically recognized by the restriction enzymes NheI 
and BamHI surrounding the cloning site and have Amp
R
. Figure II.2 represents a scheme of the 
cloning strategy of WW Clone 3 into pET 21c and the DNA sequence of WW Clone 3 with his-
tag. 
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Figure II.2: Scheme of the cloning strategy of WW Clone 3 into pET 21c and the DNA sequence of 
WW Clone 3 with His-tag. (A) Schematic representation of the cloning strategy of gene codifying WW 
Clone 3 into pET 21c vector. (B)Protein sequence from WW Clone 3 with his-tag, and the DNA sequence 
with the nucleic acids that initiate the WW Clone 3 gene in highlighted. 
 
  Amplification of the vector pEX WW Clone 3 2.2.4.2
 
The pEX WW Clone 3 was synthesized by the company Eurofins (Germany) in a 
transport plasmid pEX A2. For the initiation of the cloning of the WW Clone 3, it was necessary 
to amplify the transport vector. 
The vector was bought lyophilized and for this reason it was necessary to hydrate with 
50µl of sterile Milli-Q water, as recommended by the manufacturer. After, E. coli Top10 F‟ 
bacterial cells were transformed by electroporation.  
 
 
 Bacterial transformation by electroporation 2.2.4.3
 
It was added 1µl of the vector pEX WW Clone 3 (2.5µg) in 50µl of TOP 10F‟ 
(10
9
cfu/µg) cells E. coli, and the electroporation in mode EC1 with 1.8V of pulses as indicated 
by the manufacturer. Then, it was added in 1ml of SOC medium that was performed and 
incubated at 37°C with 220rpm for 1 hour. 
After, it was added 50µl of the culture in the plates with LB solid and 10µl of ampicillin 
(100µg/ml). It was incubated at 37°C overnight to produce individual colonies.  
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 Isolation and purification of plasmid DNA from E. coli  2.2.4.4
 
To proceed with the pre-inoculum, three colonies were picked in the plate and were 
added in 10ml of LB liquid and 10μl of ampicillin (100μg/ml) and incubated at 37°C overnight 
with 220rpm. The optical density (OD) of the growth media was measured at 600nm (OD600nm) 
and selected the one presenting the highest OD values. 
It was removed 1ml of the culture with the highest OD600nm to make a stock and it was 
centrifuged at 3826xg for 4 minutes and then, the supernatant discarded. Posteriorly, it was 
added 100μl of sterile glycerol 10% (v/v) and stored at -80ºC. 
The remainder of the culture was centrifuged at 15303xg for 10 minutes and the 
supernatant was removed. Then, the purification of plasmid DNA from E.coli cells was 
performed with Miniprep kit, according with the manufacturer (NzyTech). The plasmid DNA was 
eluted in 40μl of sterile Milli-Q water. 
 
  DNA quantification 2.2.4.5
 
The plasmid DNA concentration of the pEX WW Clone 3 was determined with the 
Nanodrop system. The purity of plasmid DNA was determined based on absorbance ratios 
260/280 and 260/230nm.  
 
 Cloning of the WW Clone 3 with the vector pET 21c 2.2.4.6
 
The enzymatic digestions of the vectors were performed with enzymes NheI and 
BamHI according to the supplier (Thermo Scientific). It was added 4.5μl of pEX WW Clone 3 
DNA with concentration of 2000ng and 15μl of pET21c_GFP (Green Fluorescent Protein) DNA 
with concentration of 3000ng. 
The samples were digested with the enzymes NheI and BamHI through the incubation 
in the Thermal Cycler at 37°C for 30 minutes, and for inactivation of the enzymes, 5 minutes at 
80°C. 
For the purification of the fragment that refers to the gene WW Clone 3 with a His-tag 
possessing a size of approximately 160bp (Figure II.2), was made an 2% agarose gel. For 
purification of the fragment of the gene pET 21c with size approximately 5400bp, was made in 
1% agarose gel. 
For a small gel, were added 35ml of gel, and 0.75μl of Greensafe premium. For a 
large gel, 80ml of gel and 1.5μl of Greensafe premium. After polymerization, to each gel added 
5μl of the marker NzyDNA ladder V or 5μl of the marker NzyDNA ladder III (NzyTech) and to 
each DNA sample was added Loading Dye Buffer in 10% of the total sample volume. As a 
control was added 1μl of the undigested vector. The gel was run in 90V for 45 minutes. 
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The gel of each digestion reaction was visualized in GelDoc and registered. The 
bands correspondents to the fragment size of interest were extracted to WW Clone 3 and the 
digested pET 21c plasmid was digested. 
For purification of the DNA from the agarose bands, the NzyGelpure kit was used. The 
procedure was followed as described by the supplier (NzyTech). The plasmid DNA and the 
insert were eluted in 30μl of sterile Milli-Q water. Then, the DNA concentration and purity were 
determined using Nanodrop described in 2.2.4.5. 
To prevent re-ligation of the vector pET 21c, a dephosphorylation procedure was 
done. It was made with 50ng of vector to three ligation reactions. 
The enzyme utilized was FastAP Thermosensitive Alkaline Phosphatase and was 
added 8.33μl of vector DNA, 2μl of buffer 1x from the FastAP Thermosensitive kit, 0.5μl of 
enzyme and up to 20μl with high quality water. The procedure was made of according with the 
protocol of the manufacturer (Thermo Scientific). 
The sample was incubated in the Thermal Cycler for 10 minutes at 37ºC and enzyme 
inactivation for 5 minutes at 75ºC. 
For the ligation of the WW Clone 3 with pET 21c, was made of two ratios 
(insert:vector) were studied: 3:1 and 5:1; and was used a negative control, NC (without insert). 
The amount of the insert was obtained through Equation 2.1: 
 
                              
     
          
 
 
For this procedure was added 4μl of vector for NC, 3:1 and 5:1; 0.7μl and 1.5μl of 
insert for 3:1 and 5:1 respectively; 2μl of Buffer 1x from T4 DNA ligase kit, T4 DNA ligase 1μl, 
and up to 20μl with Milli-Q water for NC, 3:1 and 5:1. The procedure was made according with 
the protocol of the manufacturer, and the samples were placed in the Thermal Cycler at 16°C, 
overnight. 
The next day, were prepared the samples for the electroporation according to what 
has been described in 2.2.4.3 except that were added 2µl of each ligation sample to an aliquot 
of Top10F‟. 
To determine the success of the ligation, the plates of the different ratios 
(insert:vector) were analyzed. From each plate of the 3:1 and 5:1 three colonies of each plate 
were picked, and one from NC plate. Each clone was grown in 5ml of LB liquid with ampicillin at 
37°C overnight at 220 rpm. In the next day, a stock of this culture was saved in 10% of glycerol 
(v/v) and stored at -80ºC. 
After, it was made the purification of the clones according to what has been described 
in 2.2.4.4, followed by the quantification of DNA (2.2.4.5). 
(Equation 2.1) 
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To observe the positive clones, it was made the digestion enzymes using 2µl of NheI 
and BamHI, 25µl of DNA, and 4µl of Buffer 1x Fast digest and incubated as described above, 
and visualized in 2% agarose gel. 
One clone of the plate ratio 5:1 has shown to possess the WW Clone 3 gene with the 
expected size. So, it was made the expression in E. coli BL21 (DE3) competent cells. 
It was added 1µl of the WW Clone 3 in 50µl of BL21 (DE3) E. coli, and the mixture 
proceeded for electroporation as described in 2.2.4.3. 
In the next day, it was necessary to select one colony and add in 3ml of LB with 3µl of 
ampicillin. Then, the culture was incubated at 37°C for four hours. Posteriorly, were added 500µl 
of the culture in 50ml of LB, with 50µl of ampicillin and incubated at 37°C, overnight with 
220rpm. It was made a stock at -80ºC using 10% glycerol (v/v) of the positive clone WW Clone 
3 in BL21 (DE3).  
 
 
2.2.4.6.1 Protein expression at 18°C, 25°C and 30°C 
 
For the expression of the WW Clone 3, 1 liter of LB, 1ml of ampicillin and 10ml of the 
culture were used and incubated at 37°C for three hours. Then, after obtaining an OD600nm 
between 0.6 and 0.7, 1mM IPTG (stock 1M) was added, and protein expression was attempted 
at 18°C, 25°C and 30°C. To monitor cell growth the OD600nm was measured in a cuvette 
(Spectrophotometer) and in a 96- well plate (Tecan) before and after induction, at intervals of 3, 
4, 6 and 22 hours. In these intervals, samples were normalized the growth. After, it was stored 
at -20°C. 
In the next day, the culture was centrifuged at 15303xg for 10 minutes at 4°C. The 
pellet was resuspended in 15ml of PBS buffer (10mM Sodium phosphate, 150mM NaCl, at pH 
7.4). 
 
2.2.4.6.2 Protein extraction by French Press from bacteria cellular extracts 
 
Before starting the cell lysis with FrenchPress, it was necessary to weaken the cell 
membrane with three cycles of freeze and thaw. To thaw was heated in a bath at 37°C, and for 
the freeze cells were placed at -80°C, total of 3 repetitions.  
After, cell suspension was processed in the FrenchPress to break the cell wall and the 
cell membrane of the bacteria. Then, it was added the DNase I, and was incubated in the ice for 
15 minutes. It was centrifuged in 18517xg for 15 minutes at 4°C. After, it was added the soluble 
fraction in the flasks of the Ultra-centrifuge and was made the centrifuge for 1 hour at 204710xg. 
The soluble and insoluble fraction were collected and stored at -20°C. 
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 Screening protein expression 2.2.4.7
 
2.2.4.7.1 Analysis by SDS-Page 
 
A 17.5% Polyacrylamide gel was performed, according to the supplier (Bio-Rad). For 
this method, it was necessary add Tris-Glycine buffer (25mM Tris-Base, 195mM Glycine, 40% 
Methanol) that was the transfer buffer. In the insoluble fraction, it was necessary to add 25ml of 
PBS buffer (10mM Sodium phosphate, 150Mm NaCl), to dissolve the pellet, with the help of 
vortexing. 
Posteriorly, it was added 10μl of the marker Precision Plus ProteinTM dual color 
standards with 5μl of sample buffer of β- mercaptoethanol in the gel. In each sample 5μl of β- 
mercaptoethanol were added in 30μl of sample at 18ºC, 25ºC and 30ºC. After the following 
samples were added in the gel: 10μl of after induction (AI) and before induction (BI), and 30μl of 
the soluble fraction (SF) and insoluble fraction (IF). As a control, it was used 10μl of WW Pin1 
sample (a kind gift from MSc. Ana Dias), plus 5μl of sample buffer with β-mercaptoethanol. 
Before loading the gel, the samples were boiled for 5 minutes. The gel was run in 100 V for 60 
minutes. After, it was made the coloring of the gel with Coomassie Blue R-250. (0.1% 
Coomassie Blue R-250, 0.15% Glacial acetic acid, 0.9% Methanol). 
To analyze the samples of expression of the protein in soluble and insoluble fraction of 
all temperatures through the Western Blotting method, an SDS-Page with Mini-PROTEAN Tris-
Tricine precast was made with Tris-Tricine 1x buffer, according to the supplier (Bio-Rad). 
Then, it was added 10μl of the marker Precision Plus ProteinTM Dual Color Standards 
with 5μl of sample buffer with β- mercaptoethanol in the gel. In each sample 5μl of β- 
mercaptoethanol were added in 30μl of sample at 18ºC, 25ºC and 30ºC. After 30μl of the 
following samples were added in the gel: insoluble fraction (IF) and soluble fraction (SF). As a 
control, 10μl of GFP- Pin1, plus 5μl of sample buffer with β-mercaptoethanol were used. Before 
loading the gel, the samples were boiled for 5 minutes. The gel was run in 150 V for 80 minutes. 
Through the gel SDS-Page with Mini-PROTEAN, it was possible to do the Western 
Blotting method, and it was necessary an Immobilon-PSQ Membrane (0.2μm) and Transfer 
Buffer with 40% of ethanol. The method was run in 200 mA for 35 minutes. 
To wash the membrane, TBS buffer (50mM Tris-base in 150mM NaCl at pH 7.5) was 
added, and to block the membrane, it was added the Blocking Buffer from kit of Antibody used 
in this method. Then, for the detection, it was used the Penta Anti·His HRP Conjugate Kit of 
according with the protocol of the manufacturer. After, it was added 2ml of StepTM TMB- 
Blotting. 
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2.2.4.7.2 Total protein quantification by bicinchoninic acid assay (BCA) 
 
The quantification of total protein in the soluble and insoluble fractions was made with 
the BCA (bicinchoninic acid assay) kit according with the supplier instructions. Firstly it was 
necessary to prepare a mixture with reagents A and B (A (bicinchoninic acid solution) and the 
reagent B (cooper (II) sulfate pentahydrate 4% Solution). 
Then, were added 25μl of sample and 200μl of reagents in each well. After, it is 
necessary incubate at 37ºC for 30 minutes. Posteriorly, it was measured in a 96-well plate 
reader with OD560nm (Tecan). 
It was necessary to construct a calibration curve using solutions with known protein 
concentration, bovine serum albumin (BSA) from 0 to 1 mg/ml, resulting in the calibration curve 
of with a . Some samples were diluted 1:10 and 1:100. 
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2.3 Results and discussion 
 
2.3.1 Amplification, construction and purification of plasmid DNA  
 
The vector pEX WW Clone 3 contained the gene sequence that codified for the 
protein of interest. This gene sequence was optimized to contain non rare codons. This vector 
was ready for bacteria transformation and amplification. After amplification, the vector DNA was 
quantified, and presented the following values: Concentration = 455.1ng/µl; the purity of Abs 
260/280 = 1.87 and Abs 260/230 = 2.26. After analyzing of the sample, the DNA extracted 
showed a high degree of purity.  
To clone the gene that encodes to the protein WW Clone 3 directly into the expression 
vector pET 21c, the sites of restriction enzymes NheI and BamHI were used. The pET 21c used 
in this assay, had an insert that encodes for the protein GFP-Pin1 (800bp), which had to be 
removed first. This gene was removed by the restriction enzymes NheI and BamHI. 
Subsequently to verify if the vector and insert were well cleaved, and proceed with the 
extraction, it was made an agarose gel 1% for the pET 21c with a fragment of size of 5400bp, 
and an agarose gel 2% for the fragment of WW Clone 3 with an expected size of 160bp (Figure 
II.3). 
 
 
 
Figure II.3: Agarose gel purification of the DNA fragment. (A) 2% agarose gel of the insert WW Clone 
3 with a fragment of 160bp. (B) 1% agarose gel of the pET 21c with a fragment of 5400bp. It was used the 
marker NzyDNA ladder V to the 2% agarose gel and the marker Nzy DNA ladder III to the 1% agarose gel. 
 
In order to obtain the desired fragments, we proceeded with the extraction, purification 
and quantification of the DNA. The concentration of pET 21c was 33.2ng/µl and the ratios of 
purity were Abs 260/280= 1.87 and Abs260/230= 0.52; the concentration of the insert WW 
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Clone 3 was 7.9ng/µl. Then, it was made the dephosphorylation of the vector pET 21c to 
prevent its re-ligation. 
Based on the concentration of the DNA, the ratios for ligation were determined 
between the pET 21c and WW clone 3. Two ratios (insert:vector) were attempted: 3:1 and 5:1; 
and also a negative control, NC (without insert). After the incubation of the plates, clones were 
found in all plates, but the plate 5:1 contained more.  
The concentration and purity were determined for one colony from NC and 3:1, and 
three colonies from the 5:1 ratio assay. The average concentrations employed of NC, 3:1 and 
5:1 was 90ng/µl and the average of purity Abs 260/280 was 1.90 and Abs 260/230 was 2.2. 
These concentrations were utilized to proceed with the screening of the clones by 
digestion. And after the enzyme digestion, the screening of the clones with 2% agarose gel was 
performed, where one positive clone was verified, with a fragment of 160bp correspondent to 
the WW Clone 3 (Figure II.4).  
 
 
Figure II.4: Screening of the Clones NC, 3:1 and 5:1. It was possible verify one clone positive, 5:1-2, 
that has a fragment of 160bp that corresponding to the WW Clone 3. It was used the marker NzyDNA 
ladder V.  
 
In order to make sure that was a positive clone, with correct ligation, a new screening 
was performed with a higher amount of sample (Figure II.5). 
In other clones it was possible to observe a band with 5400bp and two bands related 
to GFP- Pin1 protein which was previously in the expression vector. This must have occurred in 
the enzyme digestion process which might have been inefficient, and for that reason the vector 
may have re-ligated. It is also possible that the vector undigested was also cut during band 
extraction, due to the low resolution of the gel and the fact that the sizes are very close. Thus, in 
clone 5:1-2, the gene encoding the protein WW Clone 3 was successfully cloned into the vector 
pET 21c. 
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Figure II.5: Screening of the clone 5:1-2. A greater amount of sample was added, showing that the clone 
5:1-2 is a positive clone. It was used the marker NzyDNA ladder V.  
 
 
2.3.2 Protein expression of the clone WW Clone 3  
 
For the expression of the WW Clone 3 protein, the transformation in E. coli BL21 
(DE3) was performed. In order to assess the best temperature for expression, three different 
temperatures were studied, 18°C, 25°C and 30°C. Cell growth was monitored over time by 
measuring the absorbance at 600nm (Figure II.6). 
Before induction, the first 3 hours, the growth was at maintained 37°C, and only then, 
IPTG was added to induction. After this, growth was carried out at different temperature. During 
the first 3 hours it is possible to observe the lag phase, and after induction with IPTG a 
significant increase in the culture growing at 18°C and 25°C and a smaller increase in the 
culture growing at 30°C. After 6 hours, there was a significant increase in the cell growth for all 
temperatures, mainly at 30ºC. The last measurement at 22 hours was made, to obtain the 
maximum cell growth. The optical density was monitored simultaneously using a 
spectrophotometer and a multiplate reader, showing high similarity (Figure II.6). 
To verify the expression of the clone WW Clone 3, an SDS- Page with polyacrylamide 
gel 17.5% was performed as shown in Figure II.7. 
It was not possible to observe the band corresponding to the protein in study, due to 
presence of large amounts of other proteins or because the protein was not expressed. A 
solution of WW Pin1 (kindly provided by MSc. Ana Dias, FCT-UNL) was also added as control 
because they have the same size.  
After, a SDS- Page Tris- tricine gel was performed, which is more appropriate for 
small proteins, with the sample of soluble fraction (SF), insoluble fraction (IF) of all 
temperatures, and for the control, a sample of the protein GFP-Pin1. After, it was made a 
Western blotting method, through colorimetric detection (Figure II.8).  
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Through Western blotting method, it was not possible to detect the protein in study, 
but positive control was detected and the lower molecular weight marker was also detected. 
This might be due to some limitations of this method, if the protein of interest was produced in a 
very small amount, the detection does not occur. 
Assuming a very small amount of protein was expressed, and also to verify the 
optimum temperature of expression, it was performed total protein quantification, through the 
BCA test.   
 
 
 
Figure II.6: Graphic of cell growth by measuring the absorbance at 600nm. (S) Optical density values 
obtained during the growth of the WW Clone 3, by Spectrophotometer. (M) Optical density values obtained 
during the growth of the WW Clone 3, by a multiplate reader. 
 
 
 
Figure II.7: SDS-Page with polyacrylamide gel 17.5% to verify the expression of the clone WW 
Clone 3. Polyacrylamide gel (17, 5%) from electrophoresis, stained with Coomassie blue with the samples 
of 18ºC, 25ºC and 30ºC. The control used was the protein WW Pin1. It was used the marker Precision 
Plus Protein Dual Color Standards. 
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Figure II.8: Western Blotting method and Total protein quantification. (A) Western blotting membrane 
from the tris-tricine gel for all samples in study, with a band of a positive control, GFP-Pin1. It was used the 
marker Precision Plus Protein dual color standards. SF (soluble fraction); IF (insoluble fraction). (B) 
Column chart for total protein concentration obtained by BCA test. The concentration for soluble fraction is 
in blue and for insoluble fraction in orange. 
 
The BCA test allows us to obtain the total protein concentration in the soluble and 
insoluble fractions of the samples.  Using the calibration curve previously shown, it was possible 
to calculate the concentrations of the soluble and insoluble fractions for all temperatures above 
mentioned (18ºC, 25ºC and 30ºC). The results obtained for soluble fraction at 18ºC and 25ºC 
was approximately 35mg/ml and approximately 45mg/ml for 30ºC. In the case of insoluble 
fraction it was obtained approximately 5mg/ml for 18ºC, approximately 8mg/ml for 25ºC and 
approximately 10mg/ml for 30ºC, as is shown in the Figure II.8.   
According to the columns chart (Figure II.8), it was possible to observe that the best 
temperature is 30ºC, because the concentration of total protein is higher than at the other two 
temperatures. Although it was possible to determine the protein concentration, it was not 
possible to observe in the Western blotting, the WW Clone 3 protein. 
The protein gene from WW Clone 3, was sent for sequencing and the result was 
positive, which means that the gene codifying for the protein WW Clone 3 is present in the 
sample.  
According to the results obtained, it was not possible to continue this work. This may 
be due to the size of the protein of interest. The WW Clone 3 is a very small protein, of 
approximately 5kDa, and with a hydrophobic character, being considered difficult to express in 
E. coli. 
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2.4 Conclusions 
 
 
Several studies have been conducted with the WW domain protein, due to its 
excellent ability to establish protein-protein interactions. Protein domains are natural modulators 
of biological function through ligand binding. These domains may be engineered in order to 
generate altered activities and novel affinity reagents and provide a versatile platform to link 
individual proteins into physiologically important networks (Patel et al, 2013; Ignham et al, 
2005).  
This experimental aimed at optimizing the expression of WW Clone 3 protein, since 
another WW domain (WW Pin-1) was already previously co-expressed in our group with GFP. 
In this work we used molecular biological techniques to construct a protein expression vector 
using the expression vector pET 21c, adding to insert the gene encoding the protein WW Clone 
3. This step was successful, in the positive clone 5:1-2 it was possible to obtain the gene 
encoding the protein WW Clone 3. 
Three different temperatures were tested for expression, 18ºC, 25ºC and 30ºC, and 
through the result of the optical density absorbance, it was possible to conclude that the best 
temperature for cell growth was 30ºC. Also, we obtained the total protein concentration in the 
soluble and insoluble fractions at each temperature, and the temperature that produced a larger 
amount of total protein was at 30ºC, with approximately 45mg/ml in the soluble fraction and 
10mg/ml in the insoluble fraction. 
In conclusion, in this study it was possible to obtain the gene encoding the protein of 
interest through a sequencing confirmation, but the quantity of protein expressed was too small 
to be detected by Western blotting method, or in fact protein was not expressed. With these 
results, it was not possible to continue this work because the result was not sufficient to achieve 
the goal initially proposed; therefore, a better strategy to optimize the expression of this protein 
in a detectable amount is required.  
As a future strategy, we could try to optimize the expression using another type of 
competent cells of E. coli, and the pET System, e.g. pET 28. In addition, the concentration of 
IPTG can be adjusted; the time and the temperature of induction changed; and the gene the 
sequence can be optimized again. Other strategies could be to express the protein in insoluble 
form by decreasing the temperature of expression and subsequently try to solve the inclusion 
bodies. It can also change the position of the protein tag and its type, to a more hydrophilic, to 
provide more solubility to the protein, e.g. Ubiquitin, SUMO and GST (Glutathion- S- 
transferase); or an affinity tag to further purification.  
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III. Design, synthesis and screening of 
solid phase combinatorial libraries of 
affinity ligands towards HSA 
 
 
 
In this work two solid phase combinatorial libraries were design based on amino acids 
of the protein PAB and drugs that bind naturally to HSA, and synthesized using the Ugi and 
Triazine based reactions. Subsequently, the libraries were screened against to HSA in two 
different pH values by microscale affinity chromatography. Different pH conditions were tested 
for binding of albumin to the neonatal Fc receptor in order to try increase the half-life of drugs or 
even from the therapeutic proteins as this binding is pH-dependent. In addition, these synthetic 
ligands can serve as a new alternative for the purification of the HSA in a lower cost, more 
durability and stability manner. 
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3.1 Introduction 
 
Currently there is an increase in the popularity of low molecular weight ligands that 
mimic the action of biologics, not only for drug discovery and inhibition of enzymes, but also in 
many protein purification applications (Gupta and Lowe, 2000). 
Affinity ligands are classified into two types: biospecific and pseudobiospecific. 
Biospecific ligands are molecules derived from natural sources that have affinity for the target 
protein-binding site (e.g. natural antibody-binding molecules include the antigen, anti-antibodies, 
lectins or bacterial immunoglobulin-binding proteins). Pseudobiospecific ligands can be 
biological or non-biological molecules that have affinity to the target protein, although do not 
occur naturally in the biological systems (e.g. synthetic dyes, peptides or oligonucleotide 
aptamers) (Roque and Lowe, 2006; Roque et al, 2007). 
Employing combinatorial chemistry approaches, a new class of pseudobiospecific 
ligands, termed biomimetic has been developed, as a more advanced version of the natural 
affinity ligands (Roque et al, 2005). This class of ligands, mimic the structure and binding of 
natural biological ligands and result from the integration of rational design, combinatorial 
chemistry and screening in parallel for binding to the target protein (Sousa and Taipa, 2014; 
Roque et al, 2004).  
There are four main strategies on ligand design that can be followed: (i) use of the 
natural binding site of the biological ligands as a template; (ii) development of a novel molecule 
with the same binding of the complementary ligand for the target protein; (iii) exploitation of the 
natural biological recognition interactions between the pairs ligand and protein; and (iv) analysis 
of the structure of the target protein and selection of the best binding sites (Roque et al, 2004).  
Lowe and colleagues were pioneers in the synthesis of synthetic ligands through the 
Triazine based reaction, a type of combinatorial chemistry reaction employed on a solid support, 
for affinity purification of different target biomolecules (e.g. immobilized artificial Protein A to 
purify IgG from human plasma, ascites fluid and fetal calf serum) (Li and Lowe, 1998; Lowe et 
al, 1992; Roque et al, 2004).  
The Triazine reaction (2,4,6-trichloro-1,3,5-triazine) is based on the reactivation of the 
cyanuric chloride under relatively mild conditions. Normally, the three chloride atoms from 
cyanuric chloride can be replaced in a sequential and controlled fashion by amines in aqueous 
solution through nucleophilic substitutions; the first substitution occurs between the solid matrix 
activated with amine groups and the cyanuric chloride molecule at approximately 0ºC, the 
second (R1) at 30ºC and the last substitution (R2) occurs at 80ºC (Figure III.1) (Filippusson et 
al, 2000; Sproule et al, 2000; Teng et al, 1999; Roque et al, 2004).  
The Ugi multicomponent reaction has also been employed for the synthesis of 
combinatorial libraries of affinity ligands, and is a reaction with several advantages, as its 
simplicity, low cost and time saving (Pina et al, 2014a). Furthermore, the Ugi reaction is 
considered more flexible than the Triazine scaffold due to its structure that is less planar (Qian 
et al, 2012). Haigh and co-workers synthesized a ligand that mimics the protein L through the 
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Ugi reaction on Sepharose
TM
 solid-support. This ligand binds preferentially to the Fab domain 
over the Fc domain (Haigh et al, 2009). Therefore, this study and many others demonstrated 
that Ugi reaction can be a great alternative to synthesize synthetic ligands for different protein 
purification applications (Haigh et al, 2009; Chen et al, 2014; Pina et al, 2014a). 
 
 
 
Figure III.1: The solid phase synthesis of Triazine reaction. For occur the combinatorial synthesis of a 
Triazine-based ligand library, the cyanuric chloride compound, will be undergoes three nucleophilic 
substitution (denoted by Nü), and these nucleophiles can be amines, hydroxyls, thiols and others. For the 
first substitution, a solid matrix (sphere) with a nucleophile will react with cyanuric chloride at 0°C for 1 
hour. Subsequently two other nucleophilic substitutions will occur: R1 at 30 ° C for 24 hours and R2 at 
80ºC for 48 hours. R1 and R2 can contain a varied functional group (Lowe et al, 2000).  
 
This multicomponent reaction consists in a four-component reaction which involves a 
the strictly governed interaction primary amine, an aldehyde or ketone, an isocyanide, and a 
carboxylic acid to form a bis-amide, losing just one molecule of water during the whole process 
(Figure III.2) (Tron, 2013; Qiana et al, 2012).  
The most commonly adsorbents used on protein purification protocols are biological 
ligands which presents several limitations as higher costs associated, greater fragility and they 
are not readily amenable to scale-up. Moreover, the adsorbents based on monoclonal 
antibodies or phage display peptides are more prone to chemical and biological degradation. 
On other hand, entirely synthetic ligands presents more advantages over the biological ligands 
such as higher stability, defined chemical structure, resistance to chemical and biological 
degradation, sterilization in situ without loss of performance, durable and reusable over multiple 
cycles and can be produced with lower costs (Haigh et al, 2009; Gupta and Lowe, 2000; Teng 
et al, 1999; Lowe, 2001; Pina et al 2014b).  
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Figure III.2: Mechanism for the Ugi reaction. The reaction begins with an interaction between the amine 
and the aldehyde or ketone in a solid matrix, to give the corresponding imine (1). The imine will react in an 
acid-base reaction with the carboxylic acid to form an iminium ion (2), which is posteriorly arrested by the 
isocyanide to obtain a nitrilium ion (3). This reacts with carboxylate ion produced in the imine activation 
step to afford an imino-anhydride unstable (4), and lastly occurs the Mumm rearrangement (Image 
adapted from Tron, 2013).  
 
The most common adsorbents used on protein purification protocols are biological 
ligands which present several limitations high cost, great fragility and difficult amenable to scale-
up. Moreover, the adsorbents based on monoclonal antibodies or phage display derived 
peptides are more prone to chemical and biological degradation. On other hand, entirely 
synthetic ligands, as those based on the Triazine and Ugi scaffold, present more advantages 
over the biological ligands such as higher stability, defined chemical structure, resistance to 
chemical and biological degradation, sterilization in situ without loss of performance, durable 
and reusable over multiple cycles and can be produced at lower costs (Haigh et al, 2009; Gupta 
and Lowe, 2000; Teng et al, 1999; Lowe, 2001; Pina et al 2014b).  
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3.2 Material and methods 
 
3.2.1 Chemicals  
 
All reagents were used with a high purity and the solvents were pro-analysis. 
 
The reagents Tyramine (A1), Isopentylamine (A2), 3,4-Dimethylaniline (A3), 1,4 
Diaminobutane (A4), Phenethylamine (A5), Sulfisoxazole (A6), Amino-2-propanol (A7), 2-
aminopentane (A8), 3,4-dihydroxyhydrocinnamic acid (C1), 9- Anthracenecarboxylic acid (C2), 
4-Methylvaleric acid (C3), 3,5-Diiodosalicylic acid (C4), 4-Imidazolecarboxylic acid (C5), 
Indomethacin (C6), Arabic Acid (C7), Aspirin (C8), Nicotinic acid (C9), 3-indole acetic acid 
(C10), DL-Proline (C11), human serum albumin and bovine serum albumin (BSA) were 
purchased from Sigma- Aldrich (Portugal).  
Acetone, Epichlorohydrin, Cyanuric chloride, Isopropyl isocyanide, Phenol, Sodium 
bicarbonate (NaHCO3), Sodium periodate (NaIO4), Sodium thiosulfate (Na2S2O3), Silver nitrate 
(AgNO3), Glutaraldehyde, Glycine, Sodium Chloride (NaCl) and QuantiPro
TM
 BCA Assay Kit 
were acquired from Sigma-Aldrich (Portugal). Methanol (MeOH) and Ammonium hydroxide 
solution (NH4OH) were obtained from Roth. Dimethylformamide (DMF), Methanol (MeOH), Di- 
Sodium-hydrogen Phosphate 2-hydrate and Sodium hydroxide (NaOH) were purchased from 
VWR. Ethanol absolute PA, Sodium-di-hydrogen Phosphate 1-hydrate, Hydrochloric acid 37% 
(HCl), were acquired from Panreac (Spain).  
 
 
3.2.2 Chromatographic materials 
 
Cross linked agarose (SepharoseTM CL-6B) was acquired from GE Healthcare 
(Portugal); Captiva 96-well filtration block was purchased from Agilent Technologies (EUA); 
Half-area UV-Star® 96-well microplates and 96-well transparent microplates were obtained from 
Greiner Bio-One (Germany) and Sarstedt (Germany), respectively. 
 
3.2.3 Buffers 
 
The following buffers and reagents were used: Phosphate Buffer Saline (PBS) (10mM 
Sodium phosphate, 150mM NaCl, pH 7.4 and pH 6.0); Regeneration Buffer (0.1M NaOH in 30% 
isopropanol); 0.1M NaOH in 50% isopropanol; 0.1M glycine- NaOH at pH 9.0 in 50% Ethileno 
glycol; 0.1M Glycine – NaOH at pH 11; 0.1M HCl; 0.1M Glycine at pH 2.5; 0.2M NaOH in 50% 
isopropanol; 1M NaCl in Phosphate buffer saline. 
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3.2.4 Equipment 
 
The synthesis of the synthetic ligands on solid-phase based on Triazine and Ugi 
reaction were carried out in Incubator ZKA KS4000i (VWR);  Microplate reader TECAN Infinite 
F200 from Thermo Scientific (Portugal); Big SHOT III from Boekel Scientific. The screening was 
performed using a LMC 3000 laboratory centrifuge from Biosan.  
 
3.2.5  Methods 
 
  Epoxyactivation of agarose 3.2.5.1
 
Firstly the SepharoseTM CL-6B (83g) was washed with distilled water (10x volume of 
resin‟s weight) and filtered with the aid of a filter under vacuum. Posteriorly, the resin was 
resuspended in 83ml of distilled water and 3.3ml of 10M NaOH (40ml per 1kg of moist gel). 
After, the suspension was incubated for 30 minutes at 30ºC with orbital shaking at 200rpm. 
Then 5.97ml Epichlorohydrin (72ml per 1kg of moist gel) was added to the moist gel and 
incubated for 3 hours at 36ºC at 200rpm. In the end, the agarose was extensively washed with 
distilled water (10x resin volume). 
Afterwards, the extension of epoxyactivation was determined through the 
quantification of OH- groups released from the epoxy ring opening. Firstly 3ml of 1.3M Sodium 
Thiosulfate was added to 1g of epoxy-activated resin and incubated for 20 minutes at room 
temperature. After, the released OH- groups were titrated with 0.1M HCl until pH reached 7. The 
volume added corresponded to the number of OH- released (10μmoles per 100μl added). 
Normally, the epoxyactivation of SepharoseTM CL-6B yielded 20μmol of epoxy/g of gel (Roque 
and Lowe, 2008). In this work, the epoxy-activation obtained was 20μmol/g of agarose. 
 
  Functionalization of epoxyactivated agarose with amine groups 3.2.5.2
 
40g of epoxyactivated agarose was resuspended in 5M Ammonium hydroxide (1.5ml 
per gram of moist resin) and then incubated overnight at 40ºC with agitation at 200rpm. The 
aminated agarose was then washed with distilled water (10x resin volume) 
In order to confirm the presence of the amines in agarose, the Kaiser test was 
performed. The test allows to quantify free amines (-NH2) present in a given sample and is 
based on the reaction of ninhydrin with primary amines, which gives a characteristic dark blue 
color. Thus, 50μl of 5% ninhydrin in ethanol (w/v), 50μl of 80% phenol in ethanol (w/v) and 50μl 
of 2% 0.001M potassium cyanide in pyridine (v/v) were added to 100mg of aminated agarose. 
Then 0.9ml distilled water was added to the samples and heated in a water-bath at 100°C for 5 
minutes. A calibration curve with glycine solutions (0-5μmol/ml) was performed in triplicates of 
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                with a          . Typically, the amount of amine groups was estimated 
as 10µmol/g support. 
 
  Functionalization of epoxyactivated agarose with aldehyde groups 3.2.5.3
 
40g of epoxyactivated agarose was resuspended in 40ml 5M NaOH (1ml/g moist 
resin) and incubated overnight at 30°C with agitation at 200rpm. After, the resin was extensively 
washed with distilled water using vacuum filtration, resuspend in 40ml 0.1M sodium periodate 
(1ml/g moist resin) and incubated at 45ºC, 200rpm for 6 hours. At the end of the 
functionalization, the resin was washed with distilled water (10x resin volume). 
After functionalization, the amount of aldehyde groups was analyzed through the 
Tollens Test. The presence of a silver mirror or a black precipitate after the test reveals the 
presence of aldehyde groups (Figure III.3). Firstly 1ml of freshly prepared Tollens reagent was 
added to 1g of aldehyde-activated agarose. For the positive control it was used 1ml of 
glutaraldehyde and for the negative control was used 1g of SepharoseTM CL-6B unmodified. 
The Tollens reagent was prepared by adding 2ml of 0.2M Silver nitrate and a drop of 3M NaOH 
in a test tube, which was previously cleaned with 3M NaOH. Subsequently, 2.8% Ammonium 
hydroxide was added dropwise with constant agitation until almost all precipitate of silver oxides 
has dissolved. In order to guarantee the removal all the precipitate, 8.8% Ammonium hydroxide 
was added dropwise. Afterwards, the Tollens reagent was ready to use. 
 
 
 
Figure III.3: Tollens test of the agarose with aldehyde groups. The presence of a silver mirror or a 
black precipitate in the aldehyde- activated agarose revealed the presence of aldehyde groups.  
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 Synthesis of the solid phase combinatorial library based on the Triazine 3.2.5.4
reaction 
 
 
In order to perform the Triazine reaction, the agarose gel functionalized with amine 
groups was washed with distilled water. Then, two solutions were prepared: first a cold solution 
of 50% (v/v) acetone/distilled water with 1 molar eq. of Sodium bicarbonate relative to the 
content epoxy (1ml/g moist agarose), and a second with a solution containing Cyanuric chloride 
(5 eq. molar excess relative to epoxy content) dissolved in acetone (8.6ml/g Cyanuric chloride). 
These solutions were added to the aminated resin, followed by incubation for 1hour in ice at 
200rpm. 
Posteriorly, the agarose was washed with acetone (2x resin volume), 50% (v/v) 
acetone/ distilled water (3x resin volume) and distilled water (5x resin volume). The agarose 
functionalized with Cyanuric chloride was resuspended in 18ml 50% DMF/distilled water, and 
then with a 1-ml pipette tip that was cut 4mm, was distributed in 64 wells of a 96-well filter plate 
(0.25g/ well). After that, the end cap of the reaction block was removed to occur the solvent 
drain by gravity. Then, the end cap of the reaction block was again placed, and the amines A1 
to A8 to each column of the filter plate (2 molar eq. of each relative to epoxy content; 0.5ml/ 
well) were added (R1) (Figure III.4). Then, an upper cover was placed, and the filter plate was 
incubated for 24h at 30°C with agitation (150rpm). 
Subsequently, the ligands were washed with 50% DMF/distilled water (1x 0.75ml) and 
distilled water (4x 0.75ml). In the last wash, the solvent was left to drain by gravity. Afterwards, 
the end cap was again placed and the amines A1 to A8 were added to each well of the filter 
plate (5 molar eq. of each relative to epoxy content; 0.5ml/ well) (R2) (Figure III.4). After, the 
block was sealed and incubated for 48 hours at 80°C in the orbital shaker (150rpm). 
At the end of the reaction, the ligands were washed with 50% DMF/distilled water (5x 
0.75ml), 0.1M HCl (1x 0.75ml), distilled water (1x 0.75ml), 0.1 NaOH in 30% isopropanol (v/v) 
(regeneration buffer; 0.75ml), and finally distillated water (5x 0.75ml), and 20% ethanol (v/v) for 
store at 4ºC. 
In this reaction, all the amines (A1 to A8) were firstly dissolved in 50%DMF/distilled 
water, before add to the wells. Moreover, it was added 1M Sodium bicarbonate (1 molar eq. 
relative to epoxy) in each amine. 
Two types of negative controls were added in two different wells of the multiwell plate 
i) 0.25g SepharoseTM CL-6B ii) 0.25g Aminated agarose. 
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Figure III.4: Illustrative image of the 96-well filtration block used for the synthesis of the ligands 
based on Triazine reaction. From the top, with the order of addition of the compounds. R1 indicates the 
amines that were added to the second nucleophilic substitution and the R2 indicates the amines that were 
added to the last nucleophilic substitution used on the Triazine library. 
 
  Synthesis of the solid phase combinatorial library based on Ugi reaction 3.2.5.5
 
In order to perform the Ugi reaction, the agarose functionalized with aldehydes groups 
was washed with 20% of methanol, from 0% (v/v) to 100% (v/v) methanol. After, the agarose 
was resuspended in 24ml of 100% methanol (v/v). Thus, with a 1-ml pipette tip that was cut 
4mm, agarose was distributed in 88 wells of a 96-well filter plate (0.25g/ well), and the slurry 
was left to drain by gravity in order to remove the solvent. Then, the end cap of the reaction 
block was again placed. 
First, the amines A1 to A8 (5 molar eq. of each relative to epoxy content; 0.25ml/well) 
were added in the block (Figure III.5), to form the imine compound that is required in the Ugi 
reaction. Then, an upper cover was placed, and the filter plate was incubated for 2 hours at 
60°C with agitation (180rpm). After, the carboxylic acid compounds C1 to C11 (5 molar eq. of 
each relative to epoxy content; 0.25ml/ well) were added in the block (Figure III.5), with the 
isopropyl isocyanide (5 molar eq. relative to epoxy). Then, the block was sealed and incubated 
for 48 hours at 60°C in the orbital shaker (150rpm). 
In the end of the reaction, the ligands were washed with 1ml of the following reagents: 
100% methanol (v/v), 50% methanol (v/v), 50% DMF/distilled water (v/v), distilled water, 0.1M 
HCl, distilled water, 0.2M NaOH in 50% isopropanol (v/v), 2x distilled water and 20% ethanol 
(v/v) for store at 4ºC. 
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In this reaction, all the amines and carboxylic acid compounds were dissolved in 100% 
methanol, with the exception of C7 compound, that was dissolved in 50% methanol/distilled 
water (v/v). 
Two types of negative controls were added in two different wells of the i) 0.25g 
Sepharose
TM
 CL-6B ii) 0.25g Aldehyde-functionalized agarose. 
 
 
 
Figure III.5: Illustrative image of the 96-well filtration block used for the synthesis of the ligands 
based on Ugi reaction. From the top, with the order of addition of the compounds amine and acid 
carboxylic used in the Ugi library. 
 
  Regeneration and equilibration of the combinatorial libraries 3.2.5.6
 
 
The regeneration and equilibration of the libraries were necessary prior to screening. 
The libraries of Ugi and Triazine containing the affinity ligands and the controls were washed for 
binding with regeneration buffer (0.1M NaOH in 30% isopropanol) followed by distilled water (3 
cycles of washes, 0.75ml/well). After, the equilibration of the libraries was conducted with the 
addition of the binding buffer (15x 0.75ml/well on average). The 10mM Phosphate Buffer, 
150mM NaCl at pH 7.4 and 6.0 was used as binding buffer. In the last wash, 100μl were 
collected in a half-area UV-Star 96-Well microplate, and read at 280nm. The last wash was 
performed when the absorbance values were lower than 0.005. Then, it was added 20% 
ethanol (v/v) (0.75ml/well) in the libraries for store at 4ºC. 
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  Screening of the synthetic ligands 3.2.5.7
 
 
For the screening procedure, it was a solution of pure HSA in Phosphate Buffer at pH 
7.4 (0.25mg/ml) or Phosphate Buffer at pH 6.0 (0.25mg/ml) were prepared. After, 0.25ml of the 
solutions were loaded to each well of the combinatorial libraries. The blocks were incubated 
with the loading for 1 hour at 25ºC with agitation (200rpm). Posteriorly, the flow-through and the 
washes were collected with its respective binding buffer (8x 0.25ml). Both were collected in 96-
well transparent microplates by centrifugation at 500rpm during 1 minute. 
After, the total protein present in the samples was quantified by using the QuantiPro
TM 
BCA assay kit. Thus, 150μl of the QuantiPro
TM
 BCA reagent was added to 150μl of each 
sample added and incubated at 60ºC for 1 hour according to supplier instructions. The 
absorbance of the samples was then determined by measured at OD in the microplate reader at 
560nm, with a calibration curve using solutions with known protein concentration BSA in 10mM 
Phosphate Buffer 150mM NaCl at pH 7.4 and pH 6.0 from 0 to 200μg/ml with the values of 
                with a            and                  with a         , 
respectively. 
After the screening, the libraries were washed with 1ml of the following solvents: 0.1M 
glycine- NaOH at pH 9.0 in 50% Ethileno glycol (v/v) (1x); 0.1M Glycine – NaOH at pH 11 (1x); 
distilled water (1x); 0.1M HCl (2x); distilled water (1x); 0.1M Glycine at pH 2.5 (1x); 0.2M NaOH 
in 50% isopropanol (v/v) (2x); Phosphate buffer saline in 1M NaCl (1x). Then, it was made the 
regeneration described in 3.2.5.6. 
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3.3 Results and discussion 
 
3.3.1  Rational design of the combinatorial libraries 
 
 
In order to select the amine and carboxylic compounds to incorporate in the 
combinatorial libraries, several HSA ligands were considered. The study focused initially on 
proteins that bind to the domain II of HSA. The aim was to leave domain III, responsible for 
FcRn interaction, free to bind to the natural receptor.  
The protein PAB naturally binds in the domain II of HSA, and through of the study of 
Lejon and coworkers, it was possible to determine the amino acids involved in this interaction 
(Figure III.6) (Table III.1) (Lejon et al, 2004). To ensure greater variability of the libraries, the 
drugs that bind to Domain II of HSA were also included in the design (Table III.2). 
 
 
 
Figure III.6: Structure from the protein PAB with the amino acids that bind to the domain II of HSA. 
Representation in ribbon model of the protein PAB (green), and the selected amino acids in stick (red) with 
the code, that were introduced for the synthesis of libraries. Image built in UCSF Chimera software (PDB 
code: 1GAB) (Lejon et al, 2004; Johansson et al, 1997). 
 
Table III.1: List of the amino acids from the protein PAB that bind to the domain II of HSA (Lejon et al, 
2004).  
 
Amino acids from protein PAB 
Phenylalanine 27 
Leucine 44 
Lysine 36 
Serine 25 
Tyrosine 28 
Alanine 31, 35 
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Table III.2: List of the drugs that bind to the domain II of the HSA used in the libraries. 
Drug Reference 
3,5-Diiodosalicylic acid  Ghuman et al, 2005 
Indomethacin Ghuman et al, 2005 
Sulfisoxazole  Ascenzi et al, 2006 
Aspirin  Fanali et al, 2012 
 
  
From these amino acids and drugs, different amines (Table III.3) and carboxylic acid 
(Table III.4) were selected for the synthesis of these libraries. Aromatic moieties were also 
introduced to mimic hydrophobic interactions, to improve the variability within the libraries. 
Considering that the Ugi reaction is a multicomponent reaction, it is possible to 
incorporate three, four or even more reagents, and then have a wide variety in the final structure 
of the ligand. In this study, only two components, an amine (Table III.3) and other carboxylic 
acids were varied binding a library with 88 different affinity ligands (Table III.4). The isopropyl 
isocyanide component was kept constant (Haigh et al, 2009).  
For the Triazine reaction, eight amines were used to construct the library leading to 64 
different affinity ligands (Table III.3). In the triazine reaction, is indifferent use a type of amine in 
the first or second nucleophilic substitution, being theoretically symmetric. In the first 
substitution (R1), a lower temperature (30°C) is used to occur only a nucleophilic substitution 
between the first amine compound and the support; however, in the second substitution (R2), 
the temperature is increased (80°C), to the second compound make the remaining 
substitutions. 
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Table III.3: Amine compounds (A1- A8) used in the libraries of Ugi and Triazine with structure and name. 
The reagent who has the small rectangle indicates the amino acid which it mimics.  
 Reagent/ Amine  Reagent/ Amine 
A1 
 
 
 
Tyramine 
A2 
 
 
 
 
 
Isopentylamine 
 
 
 
Tyrosine 
 
 
Leucine 
A3 
 
 
 
 
3,4-Dimethylaniline 
A4 
 
 
1,4 Diaminobutane 
 
 
Lysine 
 
A5 
 
 
 
 
 
 
 
 
 
Phenethylamine 
A6 
 
 
Sulfisoxazole (Drug) 
 
 
 
Phenylalanine 
A7 
  
 
 
Amino-2-propanol 
A8 
 
 
 
2-aminopentane 
 
 
Serine 
 
Alanine 
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Table III.4: Carboxylic acid compounds (C1- C11) used in the libraries of Ugi reaction with structure and 
name. The reagent who has the small rectangle indicates the amino acid which it mimics. 
 Reagent/ Carboxylic acid  Reagent/ Carboxylic acid 
C1 
 
3,4-dihydroxyhydrocinnamic acid, 98% 
C2 
 
 
 
9- Anthracenecarboxylic acid 
C3 
 
4-Methylvaleric acid 
C4 
 
 
3,5-Diiodosalicylic acid – (Drug) 
C5 
 
 
4-Imidazolecarboxylic acid 
C6 
 
 
Indomethacin (Drug) 
C7 
 
 
Arabic Acid 
C8 
 
 
Aspirin (Drug) 
 
Serine 
C9 
 
 
Nicotinic acid 
C10 
 
 
3-indole acetic acid 
C11 
 
DL-Proline 
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3.3.2  Initial screening of combinatorial library with pure HSA 
 
 
All libraries were screened with pure HSA (250µg/ml) in PBS at pH 7.4 and pH 6.0. 
The screening was performed at different pH, because the binding between FcRn receptor and 
HSA is pH- dependent, causing an increase in the half-life of HSA. The receptor binds to HSA, 
after HSA enters in the endosome (pH 6.0 through pinocytosis), and then the dissociation 
occurs in the blood stream (pH 7.4), avoiding the degradation of the HSA by the lysosome. As 
one of the possible applications for HSA ligands is to increase the half-life of drugs or 
therapeutic proteins by binding to HSA, it is important that these synthetic ligands bind HSA at 
both pH.  
The unbound HSA was quantified by the QuantiPro
TM 
BCA assay and is based on the 
same principals of the bicinchoninic acid assay (BCA), however, the QuantiPro BCA gives a 
linear response from 0.5 to 30µg/ml of protein, and the BCA gives a linear response at higher 
concentrations of protein (200-1000µg/ml). Both techniques rely on the formation of a Cu
2+
 -
protein complex under alkaline conditions. Cysteine, tryptophan, tyrosine and peptide bonds are 
able to reduce Cu
2+
 to Cu
1+
, producing a purple-blue complex which absorbs at 562nm. The 
amount of reduction is proportional to protein. 
The determination of the unbound protein was determined by Equation 3.1 and 
Equation 3.2. 
 
 
                        (  )                           (  )    ∑                          (  ) 
(Equation 3.1) 
 
 
       
                        (  )
                        (  )
          (Equation 3.2) 
 
The results obtained with the Ugi library showed that the pH may be a strong influence 
on the binding of synthetic ligands for HSA. In the screening at pH 6.0 (Figure III.7), some of the 
ligands as C2A1, C4A1, C4A3 and C4A5 revealed an approximately HSA binding of 60%. In the 
screening at pH 7.4 (Figure III.8), the results were more promising with up to 100%, namely for 
C2A1, C2A5, C4A2, C4A3, C4A5 and C7A3 ligands. All ligands which obtained good 
percentage of HSA bound at pH 6.0, also performed well at pH 7.4 as C2A1, C4A3 and C4A5. 
In the Triazine library, when comparing with the Ugi library, more ligands with affinity 
to HSA were obtained. The pH continues to affect the binding potential of the ligands to HSA. In 
the screening at pH 6.0 (Figure III.9), a maximum of 66% binding to HSA was observed in some 
ligands as A1A3, A2A3, A2A6, A3A3, A3A5, A3A6, A5A3, A5A6, A6A3, A6A2 and A6A5. In the 
screening at pH 7.4 (Figure III.10), many ligands present 100% of HSA bound, namely ligands 
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A1A3, A2A3,A2A5, A3A1, A3A2, A3A3, A3A4, A3A5, A3A6, A3A8,  A5A3,  A5A5, A5A6, A6A1, 
A6A2, A6A3, A6A5 and A8A3. All ligands with good percentage of HSA bound at pH 6.0, also 
performed well at pH 7.4 as the ligands A1A3, A3A3, A6A3, A6A5, A3A6 and A5A6. The 
negative controls showed than 2% of HSA bound, meaning that unspecific binding effects with 
the solid matrix are low.  
 
 
 
 
 
 
 
Figure III.7: Screening results of Ugi reaction at pH 6.0. Screening was performed a loading pure HSA 
solution (250µg/ml) in PBS (10mM Sodium Phosphate, 150mM NaCl) at pH 6.0, to each well of a 96-well 
filtration block containing 0.25g of ligand-functionalized resin. The unbound protein from flow-through and 
washes was collected in 96-well transparent microplates and quantified by the QuantiPro
TM
 BCA method, 
measured at 560nm. (A) Amount in percentage of HSA bound in each ligand-functionalized support, using 
PBS at pH 6.0. (B) Schematic diagram representing the amount in percentage of HSA bound in each 
ligand-functionalized support, using PBS at pH 6.0. 
56 
 
 
 
 
 
Figure III.8: Screening results of Ugi reaction at pH 7.4. Screening was performed a loading pure HSA 
solution (250µg/ml) in PBS (10mM Sodium Phosphate, 150mM NaCl) at pH 7.4, to each well of a 96-well 
filtration block containing 0.25g of ligand-functionalized resin. The unbound protein from flow-through and 
washes was collected in 96-well transparent microplates and quantified by the QuantiPro
TM
 BCA method, 
measured at 560nm. (A) Amount in percentage of HSA bound in each ligand-functionalized support, using 
PBS at pH 7.4. (B) Schematic diagram representing the amount in percentage of HSA bound in each 
ligand-functionalized support, using PBS at pH 7.4. 
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Figure III.9: Screening results of Triazine reaction at pH 6.0. Screening was performed a loading pure 
HSA solution (250µg/ml) in PBS (10mM Sodium Phosphate, 150mM NaCl) at pH 6.0, to each well of a 96-
well filtration block containing 0.25g of ligand-functionalized resin. The unbound protein from flow-through 
and washes was collected in 96-well transparent microplates and quantified by the QuantiPro
TM
 BCA 
method, measured at 560nm.  (A) Amount in percentage of HSA bound in each ligand-functionalized 
support, using PBS at pH 6.0. (B) Schematic diagram representing the amount in percentage of HSA 
bound in each ligand-functionalized support, using PBS at pH 6.0. 
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Figure III.10: Screening results of Triazine reaction at pH 7.4. Screening was performed a loading pure 
HSA solution (250µg/ml) in PBS (10mM Sodium Phosphate, 150mM NaCl) at pH 7.4, to each well of a 96-
well filtration block containing 0.25g of ligand-functionalized resin. The unbound protein from flow-through 
and washes was collected in 96-well transparent microplates and quantified by the QuantiPro
TM
 BCA 
method, measured at 560nm. (A) Amount in percentage of HSA bound in each ligand-functionalized 
support, using PBS at pH 7.4. (B) Schematic diagram representing the amount in percentage of HSA 
bound in each ligand-functionalized support, using PBS at pH 7.4. 
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3.4  Conclusions 
 
 
In this chapter, two combinatorial libraries of affinity ligands based on the triazine and 
Ugi reaction were designed, synthesized and screened for binding HSA. 
The two libraries were focused on the scaffold molecules derived from Ugi reaction 
(the multicomponent reaction) and Triazine reaction (mixed and split synthesis). In order to 
create diversity in the libraries, the amine and carboxylic acid compounds were designed based 
on the i) interactions between HSA and protein PAB; ii) drugs binding to domain II of HSA. We 
focused on targeting domain II, to increase the potential application of the ligands not only the 
purification of HSA as to increasing the half-life of therapeutic proteins or increasing the 
pharmacokinetics of drugs or biodrugs. In particular, by targeting domain II, it is possible to have 
the domain III of HSA available to bind to FcRn and to survive to lysosome conditions (Figure 
I.5). Therefore, during the screening process, the tests for HSA binding were performed at pH 6 
and 7.4.   
In total, 88 and 64 synthetic ligands were produced in the Ugi and Triazine libraries, 
respectively. Subsequently, the libraries were tested against pure HSA at pH 6.0 and 7.4. All 
libraries have a series of ligands that bind well to HSA, between 50 to 100% of binding, and 
presented higher percentages of binding at pH 7.4 and pH 6.0, but principally at pH 7.4.  
In the Ugi library, C2A1, C4A1, C4A3 and C4A5 were the ligands that presented the 
higher proportion of HSA bound to both pH's (above 50%). In addition, compounds that stood 
out were the A1 (Tyramine) and C4 (3,5 Diiodosalicylic acid). The A1 compound must bind to 
HSA through hydrogen bonds or hydrophobic interactions, but the compound C4 is more to 
exert links covalent, such as hydrogen bonds, or even by dispersal forces, for present iodine in 
its structure. 
In the Triazine library, the ligands that have a percentage of HSA bound higher than 
50% in both pH values were: A1A3, A2A3, A2A6, A3A2, A3A3, A3A5, A3A6, A5A3, A5A6, 
A6A2, A6A3, A6A5 and A6A8. The compounds that stood out were the A3 (3,4 Dimethylaniline), 
A5 (Phenethylaniline) and A6 (Sulfisoxadole). Through the structure of the compounds A3, A5 
and A6, the interaction with HSA may be by hydrogen bonds or intermolecular forces and 
hydrophobic interactions. 
The synthetic ligands showed a percent bound to HSA at higher pH 7.4, in this way, 
this pH was chosen to continue the studies to test the selectivity of the ligands, in order to re-
synthesize and re-screen the lead ligands to HSA and confirm the reproducibility of the results. 
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IV. Purification of HSA with synthetic ligands 
 
The aim of this chapter is to evaluate the selectivity of the synthetic ligands based on 
Ugi and Triazine reactions for HSA binding. The combinatorial libraries were screened against 
pure IgG. Subsequently the lead ligands were selected, re-synthesized and re-screened against 
HSA and IgG to confirm the reproducibility of the results. Afterwards, a single elution condition 
was attempted to recover HSA and IgG in on-column format employing a single elution 
condition at low pH. 
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4.1  Introduction 
 
 
HSA is a protein frequently found in plasma and, together with immunoglobulins, 
constitutes 80% of all plasma proteins. Moreover, HSA is also found in tissues and bodily 
secretions throughout the body, being an excellent biomarker and also a therapeutic agent in 
several conditions (Denizli, 2011; Rajak et al, 2013).  
The plasma proteins have a wide variety of concentrations (from less than 1mg/ml to 
40g/l), becoming its fractionation a major challenge (Denizli, 2011). In addition, the removal of 
abundant serum proteins can help in the discovery and detection of less abundant proteins 
which may serve as disease markers (Steel et al, 2003). Many therapeutic products can be 
obtained from human plasma. Purification of albumin is very important for therapeutic 
applications and to study other plasma proteins, which may be masked by the high amount of 
HSA found in plasma. Therefore, it is necessary to develop purification methods selective for 
HSA, with the potential of reuse and protein recovery, at lower costs. Three industrial 
techniques are well established for the purification of albumin from serum or plasma: (i) ethyl 
alcohol fractionation (Cohn method), (ii) heat shock and (iii) chromatography (Denizli, 2011).  
The ethyl alcohol fractionation was developed by Cohn and colleagues, through a 
process that consist in the difference of solubility of albumin and other plasma proteins based 
on pH, ethanol concentration, protein concentration, temperature and ionic strength. This 
method can produce a large volume of fractionated plasma and may be regarded as safe for 
therapeutic use. However, the Cohn method requires demanding refrigeration systems (e.g. 
cold areas or refrigerated tankers), there is the risk of protein denaturation, and needs high 
quality starting material (Tanaka et al, 1998; Denizli, 2011). 
The thermal shock method is also very used to purify HSA due to its higher thermal 
stability. Plasma proteins are exposed to a very high temperature (60ºC), and HSA does not 
denature readily as opposed to the other plasma proteins which rapidly denature becoming 
insoluble in such conditions. Normally, the purity of a heat shock HSA is greater than 98% 
(Denizli, 2011). 
A wide variety of chromatographic techniques may be used for the albumin purification 
(Matejtschuk, et al, 2000). Berglöf, in 1983, described a chromatographic procedure to purify 
albumin from plasma fractionation. Plasma is transferred into the process buffer by gel filtration. 
After removal of the euglobulin fraction by precipitation, the plasma is added to a column 
packed with an anion exchanger adsorbent.  This separation medium binds the albumin under 
starting conditions but allows the IgG fraction to pass through. The bound albumin fraction is 
eluted for further purification on the cation exchanger before final polishing on the gel filtration 
medium. Pure albumin is bottled and pasteurized (60°C for 10 hours) in accordance with the 
European Pharmacopoeia (Berglöf,et al, 1983). 
Affinity chromatography is a powerful technique for the purification of many proteins 
being based on highly specific molecular recognition (Denizli, 2011). Currently there are on the 
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market a few HSA purification kits (Table IV.1) based on affinity chromatography. The 
immobilized Cibacron Blue F3G-A, a sulfonated triazine dye, is one of the earliest examples of 
the use of synthetic ligands in affinity chromatography for isolation and purification of HSA 
(Williams et al, 2014). This Dye-ligand adsorbent offers many advantages such as the 
resistance to chemical and biological degradation and low cost (Zhixin and Kongchang, 1993). 
However, the heterogeneity and low purity of the Cibacron dye can affect its use in the 
introduction of the purification of HSA at production scale for clinical use (Burnouf and 
Radosevich, 2001). The Albupure kit by triazine method, is a high-performance affinity capture 
adsorbent, however, it was designed for the purification of albumin fusion proteins. 
The process of using immunoaffinity resins for the purpose of selectively purify or 
remove HSA from solution is also well established. In the market, there are several immuno-
adsorbents, such as Vivapure® kit from Vivascience, and the Anti-HSA IgY Coupled Beads kit 
from GenWay. Nevertheless the use of biological ligands is very expensive and the scale-up is 
limited (Curling, 2004).  
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Table IV.1: HSA purification kits currently available on the market based on affinity chromatography. The structures were designed in MarvinSketch, ChemAxon. 
Product Structure Advantage Disadvantage 
Cost 
(USD) 
Company 
AlbuPure® N/A 
 Robust and long-life 
adsorbent; 
 Colorless ligands; 
 High dynamic binding 
capacities. 
 
 Low 
selectivity for 
human 
plasma. 
 
 
 15.40/ml ProMetic 
Mimetic 
Blue® P6XL 
 
 
 HSA and albumin 
related proteins from 
variety of sources; 
 Robust and long life 
adsorbents; 
 High purity; 
 High sensitive ELISA 
assay. 
 Low 
selectivity. 
 
12.60/ml ProMetic 
Cibacron 
Blue 3GA 
 
 
 
 Purification of HSA 
and others proteins 
and enzymes; 
 Resistance to 
chemical and 
biological degradation.  
 Low 
selectivity; 
 Toxicity of 
the dyes; 
 Low purity; 
 Usage limit. 
228.99/g 
Sigma 
Aldrich 
Capto Blue 
 
 
 
 Resistance and long 
life adsorbents; 
 Chemically stable; 
 Low cost. 
 Low 
selectivity; 
 Toxicity. 
 
7.63/ml 
GE 
Healthcare 
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4.2  Material and methods 
 
4.2.1  Chemicals  
 
All reagents were used with a high purity and the solvents were pro-analysis. 
 
The reagents Isopentylamine (A2), 3,4-Dimethylaniline (A3), 1,4 Diaminobutane (A4), 
Phenethylamine (A5), Sulfisoxazole (A6), 2-aminopentane (A8), 9- Anthracenecarboxylic acid 
(C2), 3,5-Diiodosalicylic acid (C4), Arabic Acid (C7), 3-indole acetic acid (C10) , human serum 
albumin, IgG from human serum and bovine serum albumin were purchased from Sigma- 
Aldrich (Portugal).  
Acetone, Epichlorohydrin, Cyanuric chloride, Isopropyl isocyanide, Phenol, Sodium 
bicarbonate (NaHCO3), Sodium periodate (NaIO4), Sodium thiosulfate (Na2S2O3), Silver nitrate 
(AgNO3), Glutaraldehyde, Glycine, Sodium Chloride (NaCl) and QuantiPro
TM
 BCA Assay Kit 
were acquired from Sigma-Aldrich (Portugal). Methanol (MeOH) and Ammonium hydroxide 
solution (NH4OH) were obtained from Roth. Dimethylformamide (DMF), Methanol (MeOH), Di- 
Sodium-hydrogen Phosphate 2-hydrate and Sodium hydroxide (NaOH) were purchased from 
VWR (Portugal). Ethanol absolute PA, Sodium-di-hydrogen Phosphate 1-hydrate, hydrochloric 
acid 37% (HCl) were acquired from Panreac (Spain).  
 
4.2.2  Chromatographic materials 
 
Cross linked agarose (Sepharose
TM 
CL-6B) was acquired from GE Healthcare; 
Captiva 96-well filtration block was purchased from Agilent Technologies (USA); Half-area UV-
Star® 96-well microplates and 96-well transparent microplates were obtained from Greiner Bio-
One (Germany) and Sarstedt (Portugal), respectively. Agilent bond Elut 3ml and Frits from 
Agilent Technologies (USA).  
 
4.2.3  Buffers 
 
The following buffers and reagents were used: Phosphate Buffer Saline (PBS) 
(Sodium phosphate 10mM, 150mM NaCl, pH 7.4 and pH 6.0); Regeneration Buffer (NaOH 
0.1M in 30% isopropanol). The buffers used in the elution step were 0.1M Glycine- HCl at pH 
2.5 and Tris (hydroxylmethyl) aminomethane- base at pH 9.0 for neutralization of eluted 
samples. 
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4.2.4 Equipment 
 
The synthesis of the synthetic ligands on solid-phase based on Triazine and Ugi 
reaction were carried out in Incubator ZKA KS4000i from VWR (Portugal). Microplate reader 
TECAN Infinite F200 from Thermo Scientific (Portugal); Big SHOT III from Boekel Scientific and 
LMC 3000 laboratory centrifuge from Biosan. 
 
4.2.5 Methods 
 
 Screening against pure IgG 4.2.5.1
 
 
The two combinatorial libraries produced in Chapter 3 were screened for binding to 
pure human IgG at pH 7.4. The procedure was similar to 3.2.5.7. After, proceeded with the 
selection of the lead ligands, its synthesis, and re-screened against HSA and IgG to confirm the 
previous results. 
 
 Re-synthesis of the lead ligands based on Triazine reaction 4.2.5.2
 
Cyanuric chloride-modified agarose was prepared according to 3.2.5.4. After, 6g of 
agarose was weight to different flask.  Subsequently, the amines (2 molar eq. of each relative to 
epoxy content; 1ml/g of resin/flask) were added in its corresponding flask, for the first 
nucleophilic substitution (R1) for 24 hours at 30°C with agitation (150rpm).   
Posteriorly, the ligands were washed with 50% DMF/distilled water (5x resin volume) 
and distilled water (5x resin volume). Then, the second amines (R2) (5 molar eq. of each 
relative to epoxy; 1ml/g of resin/volume) were added and incubated at 80ºC for 48 hours, in the 
orbital shaker (150rpm). 
All the amines used in these reactions (Table IV.2) were dissolved in 50% 
DMF/distilled water (v/v). Moreover, Sodium bicarbonate 1M (1 molar eq. relative to epoxy; 
1ml/g of resin/volume) was added in each amine. 
At the end of the reaction, the ligands were washed with 50% DMF/distilled water (5x 
resin volume), 0.1M HCl (1x resin volume), distilled water (resin volume), Sodium hydroxide 
0.1M in 30% isopropanol (v/v) (regeneration buffer; 1x resin volume) distillated water (5x resin 
volume), 20% ethanol and stored at 4ºC. 
Two types of negative controls were added in two different wells i) 0.25g Sepharose
TM
 
CL-6B ii) 0.25g Aminated agarose. 
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Table IV.2: List of amines used in the Triazine synthesis. 
Nomenclature Reagents/ Amine 
A1 Tyramine 
A2 Isopentylamine 
A3 3,4-Dimethylaniline 
A4 1,4 Diaminobutane 
A5 Phenethylamine 
A6 Sulfisoxazole 
A7 Amino-2-propanol 
A8 2-aminopentane 
 
 
 Re-synthesis of lead ligands based on the Ugi reaction 4.2.5.3
 
 
The Aldehyde-functionalized agarose was prepared according to 3.2.5.3. After, the 
agarose functionalized with aldehydes was washed with methanol, from 0% (v/v) to 100% (v/v) 
methanol with increments of 20%. Then, 6g of agarose was weighted to each flask. Thus, the 
amines (5 molar eq. of each relative to epoxy content; 1ml/g resin/volume) were added in its 
corresponding flask, and incubated for 2 hours at 60ºC in the orbital shaker (180rpm). After, the 
carboxylic acid compounds (5 molar eq. of each relative to epoxy content; 1ml/g resin/volume) 
were added together with isopropyl isocyanide (5 molar eq. relative to epoxy content, 1ml/g 
resin volume). In this reaction, all the amines and carboxylic acid compounds used (Table IV.3) 
were dissolved in 100% methanol, with the exception of C7 compound, that was dissolved in 
50% methanol/distilled water (v/v). Then, the flasks were incubated for 48 hours at 60°C in the 
orbital shaker (150rpm). 
At the end of the reaction, the ligands were washed with 1x resin volume of the 
following reagents: 100% methanol (v/v), 50% methanol (v/v), 50% DMF/distilled water (v/v), 
distilled water, 0.1M HCl, distilled water, 0.2 M Sodium hydroxide in 50% isopropanol, 2x 
distilled water and 20% ethanol for store at 4ºC. 
Two types of negative controls were added in two different wells i) 0.25g Sepharose
TM
 
CL-6B ii) 0.25g Aldehyde-functionalized agarose. 
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Table IV.3: List of Carboxylic acid and amine used in the Ugi synthesis. 
Nomenclature 
Reagent/Carboxylic 
acid 
Nomenclature Reagent/Amine 
C2 
9- 
Anthracenecarboxylic 
acid 
A1 Tyramine 
C4 
3,5-Diiodosalicylic 
acid 
A2 Isopentylamine 
C7 Arabic Acid A3 3,4-Dimethylaniline 
C10 3-indole acetic acid A5 Phenethylamine 
 
 
  Re-screening of the lead ligands against pure HSA and pure IgG 4.2.5.4
 
 
Firstly 0.25g of ligand-functionalized agarose and negative controls (SepharoseTM 
CL-6B; Aminated agarose; Aldehyde-functionalized agarose) were added in each well in a 96- 
well filter microplate for the regeneration and equilibration of the ligands according to 3.2.5.6. 
The ligands were then re-screened for binding pure HSA and pure IgG to confirm the 
previous results. The lead ligands were added in triplicate in two blocks, being that in the first 
block was tested against pure HSA in 10mM Phosphate Buffer, 150mM NaCl at pH 7.4 
(0.25mg/ml) and in the other block was tested against pure IgG in 10mM Phosphate Buffer, 
150mM NaCl at pH 7.4 (0.25mg/ml). The procedure was similar to 3.2.5.7. 
 
 
  Screening of the lead ligands in on-column format 4.2.5.5
 
 
For the ligands A3A2 and A6A5 that were selected for binding HSA selectively, 0.5g of 
ligand-functionalized agarose was packed in a small column, in duplicate. For each ligand, two 
columns were made, one to test against HSA and other to test against IgG. Then, the columns 
were washed with regeneration buffer (0.1M NaOH in 30% isopropanol) followed by distilled 
water (3 cycles of washes, until the maximum amount of column). After, the resins were 
equilibrated with the addition of the binding buffer with 10mM Phosphate Buffer 150mM NaCl at 
pH 7.4 (5 times until the maximum amount of column). In the last wash, 100μl of each sample 
was collected in a half-area UV-Star 96-Well microplate, and the absorbance was read at 
280nm. The washes came to an end when they reached a lower absorption than 0.005. 
Then 0.5ml of pure HSA (0.25mg/ml) 10mM Phosphate Buffer 150mM NaCl at pH 7.4 
was loaded in the column and 0.5ml of pure IgG (0.25mg/ml) in 10mM Phosphate Buffer 
150mM NaCl at pH 7.4 was added in other column. Posteriorly, several washes with 10mM 
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Phosphate Buffer 150mM NaCl at pH 7.4 (8x 1ml) were performed. After, the total protein was 
quantified on the samples using the QuantiPro
TM
 BCA assay kit. For this 150μl of the each 
sample was added in a transparent microplate , and then, 150μl of the QuantiPro
TM
 BCA 
reagent was added to each sample and incubated at 60ºC for 1 hour according to supplier 
instructions. The absorbance of the samples was then determined in the microplate reader at 
560nm, with a calibration curve using solutions with known protein concentration BSA in 10mM 
Phosphate Buffer 150mM NaCl at pH 7.4 from 0 to 200µg/ml with the values of           
       with a          . 
 
  Elution of the pure HSA and pure IgG in on-column format 4.2.5.6
 
 
After the screening on-column, 0.5ml 0.1M Glycine- HCl at pH 2.5 was added in each 
column with the lead ligands (A3A2 and A6A5) and collected in 1.5 ml microcentrifuge tubes. 
This procedure was performed 5 times. To avoid denaturation of the eluted proteins,1M Tris-
base pH 9.0 was added to collect the elution fractions, to adjust the pH value to 7. The analysis 
of the samples was made using the QuantiPro
TM
 BCA assay kit. Thus, in a transparent 
microplate 150μl of the each sample was added followed by 150μl of the QuantiPro
TM
 BCA 
reagent and then incubated at 60ºC for 1 hour according to supplier instructions. The 
absorbance of the samples was then determined in the microplate reader at 560nm. It was 
necessary to construct a calibration curve using solutions with known protein concentration 
(BSA) in 0.1M Glycine- HCl at pH 2.5 from 0 to 190μg/ml with the values of            
        with a         . In each samples of the calibration line was added 0.05ml 1M Tris 
(hydroxylmethyl) aminomethane at pH 9.0. 
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4.3  Results and discussion 
 
The two combinatorial libraries based on the Ugi and Triazine reaction previously 
tested against HSA (Chapter 3) were assessed for binding human IgG. 
The binding assays were performed at pH 7.4, and the results were compared with the 
screenings performed against HSA at pH 7.4 (Chapter 3). The quantification of the bound IgG 
and the percentage bound were determined by Equations 3.1 and 3.2, respectively.  
The enrichment factor was determined through Equation 4.1. In the enrichment factor, 
all values higher than 1 mean that a ligand preferentially binds to HSA over IgG. 
 
                  
          
           
              (Equation 4.1) 
 
 
In the Ugi library, from the 28 ligands that showed more than 20% of binding to HSA 
and that were compared with the results obtained with the screening against IgG (Figure IV.1), 
14 ligands had an enrichment factor of equal or more than 1. The ligands C4A3 and C8A5 
presented the same percentage of binding between the HSA and IgG. Furthermore, ligands 
C4A3 and C8A5 are the ones that had an enrichment factor of 1. 
In the Triazine library, 23 ligands that showed more than 50% of binding to HSA and 
that were compared with the results obtained with the screening against IgG (Figure IV.2). All 
chosen triazine ligands have a greater percentage of binding to HSA when compared with the 
binding to IgG, except the A8A6, which consequently has an enrichment factor less than 1. 
As the ligands have only been screened once against HSA and IgG, it is fundamental 
re-synthesize and re-screen the best ligands in order to determine the reproducibility of results. 
The criteria used to select the best ligands were different for each library and are presented in 
Table IV.4. The structure of the ligands was also taken into consideration to ensure higher 
diversity. 
From the selectivity criteria, the 14 Ugi ligands initially selected were narrowed to 5, 
since some of the ligands did not display relevant structural differences. For the 22 Triazine 
ligands, 8 were selected based on selectivity criteria (Table IV.4). The Triazine ligand A5A5 was 
eliminated by presenting a very hydrophobic structure and the ligands A2A3 and A5A6 were 
eliminated due structure similarity with ligands A3A2 and A6A5, respectively. The negative 
controls had less than 10% of IgG bound, meaning that the solid matrix is not involved in the 
interaction with IgG as already observed for HSA. Therefore, a total of 5 Ugi ligands and 8 
Triazine ligands were re-synthesized and re-screened at pH 7.4. 
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Figure IV.1: Screening results of putative Ugi ligands against IgG at pH 7.4. Screening was performed 
by adding a loading with pure IgG (250µg/ml) in PBS (10mM Sodium Phosphate, 150mM NaCl at pH 7.4), 
to each well of a 96-well filtration block containing 0.25g of ligand-functionalized resin. The unbound 
protein from flow-through and washes was collected in 96-well transparent microplates and quantified by 
the QuantiPro
TM
 BCA method, measured at 560nm. (A) The 28 selected ligands that have more than 20% 
binding to HSA at pH 7.4, compared with the results obtained from the screening against IgG. (B) 
Enrichment factor of each selected ligand. 
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Figure IV.2: Screening results of putative Triazine ligands against IgG at pH 7.4. Screening was 
performed by adding a loading with pure IgG (250µg/ml) in PBS (10mM Sodium Phosphate, 150mM NaCl 
at pH 7.4), to each well of a 96-well filtration block containing 0.25g of ligand-functionalized resin. The 
unbound protein from flow-through and washes was collected in 96-well transparent microplates and 
quantified by the QuantiPro
TM
 BCA method, measured at 560nm. (A) The 23 selected ligands that have 
more than 50% binding to HSA at pH 7.4, compared with the results obtained from the screening against 
IgG. (B) Enrichment factor of each selected ligand. 
 
Table IV.4: Criteria used for the selection of best ligands. 
Ligand % Bound HSA Enrichment Factor 
Ugi           
Triazine           
 
 
The lead ligands were re-synthesized and re-screened against pure HSA and pure 
IgG in triplicate, to confirm the previous results (Figure IV.3 and Figure IV.4). Although The Ugi 
lead ligands presented promising percentage of binding to HSA they also showed a strong 
binding to IgG. Ligand C7A3 has the better result with a 1.3 of enrichment factor, but the 
difference in binding percentage between HSA and IgG is only 22%. Except for C2A1 binder, all 
the other ligands showed a stronger binding to HSA rather than for IgG, but with a small 
difference. The results obtained with the Triazine ligands revealed to be more promising than 
73 
 
the results obtained with Ugi ligands. The triazine ligands showed a higher percentage of 
binding to HSA than for IgG, having an enrichment value of at least 1.5, with the exception of 
ligands A4A3 and A7A3. The ligands highlighted are the A3A2 and A6A5, with a difference of at 
least 50% higher for HSA than for IgG. 
The fact that some ligands did not provide the same results as the previous screening 
for IgG, might be due to an inefficient regeneration. For this reason, some contaminants might 
be present thus preventing the binding to IgG. This shows the importance of re-synthesize and 
re-screen new ligands, to confirm the reproducibility of the results. Nonetheless most of the 
ligands of both syntheses showed an enrichment factor higher than 1 which indicates that they 
bind more to HSA than to IgG.  Ligands A3A2 and A6A5 showed the most consistent values of 
enrichment factor 3.0 and 2.1, respectively. Therefore, these ligands were chosen to proceed 
with the work. 
 
 
Figure IV.3 : Screening results of the putative lead ligands of Ugi against HSA and IgG at pH 7.4 
(n=3). Screenings were performed by adding a loading with pure HSA (250µg/ml) and pure IgG (250µg/ml) 
in PBS (10mM Sodium Phosphate, 150mM NaCl) at pH 7.4, to each well of a 96-well filtration block in 
triplicate containing 0.25g of ligand-functionalized resin. The unbound protein from flow-through and 
washes was collected in 96-well transparent microplates and quantified by the QuantiPro
TM
 BCA method, 
measured at 560nm. (A) Percentage of HSA and IgG bound on each ligand. (B) Results of the Enrichment 
factor of each selected ligand (2
nd
 screening), and the previous results obtained (1
st
 screening). 
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Figure IV.4: Screening results of the putative lead ligands of Triazine against HSA and IgG at pH 7.4 
(n=3). Screenings were performed by adding a loading with pure HSA (250µg/ml) and pure IgG (250µg/ml) 
in PBS (10mM Sodium Phosphate, NaCl 150mM) at pH 7.4, to each well of a 96-well filtration block in 
triplicate containing 0.25g of ligand-functionalized resin. The unbound protein from flow-through and 
washes was collected in 96-well transparent microplates and quantified by the QuantiPro
TM
 BCA method, 
measured at 560nm. (A) Percentage of HSA and IgG bound on each ligand. (B) Results of the Enrichment 
factor of each selected ligand (2
nd
 screening), and the previous results obtained (1
st
 screening). 
 
In order to confirm the results with the ligands A3A2 and A6A5, a new screening in on-
column format was carried out with HSA and IgG. When making the screening in block, it is first 
necessary to incubate the proteins with the adsorbents for 1 hour and subsequently centrifuge 
to collect the samples. When employing the screening on column, the adsorbents are packed in 
the column, thus allowing the flow of the solutions through the action of gravity. 
The results obtained with the two independent screenings are shown in Figure IV.5, 
together with the results previously obtained from the screening on the block.  Ligand A3A2 
revealed 100% binding to HSA while for IgG the binding was only 43%, which corresponds to 
252µg/g resin and 133µg/g resin, respectively. For ligand A6A5, it was obtained 99% binding to 
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HSA and 53% for IgG binding was only. This corresponds to 250µg/g resin and 163µg/g resin, 
respectively. The amount of protein bound in µg/g of resin was determined through the Equation 
4.2. The results obtained in column when compared with the results obtained in the screening in 
block (previous experiment) were similar, being therefore consistent results. 
A single elution condition was tested, employing a typical elution in affinity 
chromatography assays (low pH). 
 
 
                        (           )  
                         (  )    ∑                        (  )
          
 
 
 
 
 
Figure IV.5: Screening results of triazine lead ligands on-column (n=2).  Screenings were performed 
by adding a loading with pure HSA (250µg/ml) and pure IgG (250µg/ml) in PBS (10mM Sodium 
Phosphate, 150mM NaCl) at pH 7.4, to each column containing 0.5g of ligand-functionalized resin. The 
unbound protein from flow-through and washes was collected in 96-well transparent microplates and 
quantified by the QuantiPro
TM
 BCA method, measured at 560nm. (A) Amount in µg/g resin of HSA and IgG 
on-column (n=2) and in block of each lead ligand (n=3) (B) Percentage of HSA and IgG bound on-column 
(n=2) and in block (n=3) of each lead ligand. 
(Equation 4.2) 
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The quantification of the protein eluted from the columns was determined by 
QuantiPro
TM
 BCA method in the microplate reader at 560nm, using Equations 4.3, 4.4 and 4.5.   
 
 
                         (  )  ∑                        (  )        (Equation 4.3) 
 
 
 
         
                         (  )
                       (  )
                  (Equation 4.4) 
 
 
 
                         (          )   
∑                        (  )
           
    (Equation 4.5) 
 
 
The percentage of protein eluted from A3A2 ligand were only 17% HSA and 22% IgG 
(46µg/g resin and 33µg/ g resin, respectively) (Figure IV.6).  For A6A5 ligand, it was possible to 
elute 2% HSA and 15% IgG (6µg/g resin and 26µg/g resin, respectively). As the optimization of 
the elution profile from an affinity is usually a trial and error procedure, further studies need to 
be performed to selectively recover the bound HSA. 
Ligand A3A2 is composed by 3.4-Dimethylaniline as amine R1 and the compost 
isopentylamine as amine R2, which mimic the leucine amino acid. Ligand A6A5 has the drug 
sulfisoxazole as amine R1 and the compost phenethylamine as the amine R2, which mimic the 
phenylalanine amino acid. Both ligands possess aromatic rings (Figure IV.7), which can 
establish hydrophobic interactions with HSA and IgG. 
Therefore, it is important to consider elution conditions that promote a decrease in 
hydrophobic effects. In Table IV.5 are listed the common elution buffers employed during HSA 
recovery from the commercial adsorbents, which also possess hydrophobic structures. 
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Figure IV.6: Elution results of triazine lead ligands. After screening, the HSA and IgG bound to ligand-
functionalized supports were eluted by adding 0.5ml 0.1M Glycine- HCl at pH 2.5 to each column. This 
procedure was performed 5 times. The eluted proteins were collected in 1.5ml tubes and after, it was 
necessary add 1M Tris -base at pH 9.0 to neutralize the samples. Posteriorly, the samples were analyzed 
in 96-well transparent microplate and quantified by the QuantiPro
TM 
BCA method, measured at 560nm. (A) 
Amount in μg/g resin of HSA and IgG eluted in each ligand. (B) Percentage of HSA and IgG eluted on 
each ligand. 
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Table IV.5: List of the elution buffers used in kits to purify HSA existing in the market 
Product Elution Buffer Company 
AlbuPure® 
150mM Ammonium acetate, 
10mM Sodium caprylate, pH 6.0. 
ProMetic 
Mimetic Blue® P6XL 
25mM Sodium phosphate, 
150mM NaCl, 30mM Sodium 
caprylate, pH 6.0. 
ProMetic 
Cibacron Blue 3GA 
0.01M Tris-Chloride acid pH 7.5-
8.0, 1.5M NaCl. 
Sigma Aldrich 
Capto Blue 
50mM Sodium phosphate, 1.5M 
Potassium chloride (KCl), pH 6.0. 
GE Healthcare 
 
 
 
 
 
 
Figure IV.7: Lead ligands structure immobilized on agarose. The grey sphere is a schematic 
representation of an agarose bead. The structures were designed in MarvinSketch, ChemAxon. 
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4.4 Conclusions 
 
A total of 17 ligands were selected in chapter 3 on the basis of a high binding to HSA 
at both pH 6.0 and 7.4, being 4 from the Ugi library and 13 from the Triazine library. 
In this chapter, the possibility to further develop these ligands as affinity reagents for 
HSA purification was explored. Therefore, the 152 ligands from the two libraries were screened 
for binding IgG at physiological conditions.  
In general, ligands with a high affinity towards HSA tend to be hydrophobic, it is 
necessary to test the selectivity of the ligands. Human IgG was used, because it is also found in 
plasma in high amounts. 
After the screening against IgG, a selectivity criterion was used in this work, and 13 
ligands were chosen to proceed, as they presented the highest enrichment factors, i.e., 
preferential binding to HSA. Those were re-synthesized and re-screened in the block against 
HSA and IgG and two ligands were selected on the basis of the consistent results achieved.  
The two ligands, A3A2 and A6A5, were packed in a small column and a preliminary 
single elution condition was tested, showing that further optimization of buffers is needed.  
However, such small synthetic ligands appear as a promising alternative to purify 
HSA, due to its high stability and strength and can be reused. Moreover, it can be produced at a 
lower cost compared to the existing options. 
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V. General conclusions 
 
With an average consumption in the developed world of 200-400kg/million inhabitants, 
and almost $6.9 billion in the industry supplies products to more than one million inhabitants 
each year, HSA is emerging in the pharmacokinetic industry, due its fantastic capacity to carry a 
large and wide variety of compounds (Curling, 2004). 
In biotechnology and biomedical applications, HSA can be founded in three different 
ways, namely HSA alone, HSA in fusion with biological proteins/peptides, or HSA complexes, 
being of much interest in the therapeutic area. 
 HSA is an important biomarker of many diseases, such as cancer, rheumatoid 
arthritis, and ischemia, and is also very used clinically to treat several diseases, like 
hypovolemia, shock, burns, trauma, hemorrhage, nutrition support and many others. Moreover, 
many therapeutic proteins or drugs can interact with HSA (by fusion or complexes) as part of its 
daily round through the circulation blood, increasing its half-life time, due the pH-dependent 
binding, between the FcRn receptor and the domain III of HSA (Fanali et al, 2012; Nilvebrant 
and Hober, 2013). 
HSA has innumerous applications in the biomedical market, and can be found as HSA 
alone, HSA fused with biological proteins/peptides or HSA complexes, due to its high demand 
HSA has a great interest in the therapeutic area. 
Due to high variability applications to HSA, is an effective strategy improving the 
pharmacokinetic properties of the drugs, increase the half-life of many therapeutic proteins, and 
also develop new alternatives for the purification of the HSA. For this reason, the aim of this 
work was the development of biological and synthetic affinity ligands towards HSA. 
The first part of the work was to optimize the expression of a biological ligand called 
WW Clone 3, a small protein previously selected by phage display to present affinity towards 
HSA. This ligand is of biological origin, and for that reason has low toxicity and having a small 
size can be synthesized biologically and chemically.  
The gene codifying the protein of interest was cloned into the vector expression 
(vector pET 21c, Amp
R
), and then expressed in E. coli strain BL21 (DE3), at three different 
temperatures (18ºC, 25ºC and 30ºC) with IPTG induction. It was found that the best 
temperature for cell growth was 30ºC, producing a larger amount of total protein with 
approximately 45mg/ml in the soluble fraction and 10mg/ml in the insoluble fraction. However, it 
was not possible to detect the protein in any of the above fractions This might be indicate that 
the protein was produced in a very small amount, or in fact protein was not expressed. With 
these results, it was not possible to continue this work because the result was not sufficient to 
achieve the goal initially proposed. For that reason, it is necessary a new strategy to optimize 
the expression of this protein. 
The second part of the work was to develop synthetic ligands with affinity for HSA, 
based on the synthesis of two solid-phase combinatorial libraries. These ligands are more 
resistant and are more easily produced, and can be used for various applications. However, in 
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order to develop these ligands as affinity reagents for HSA purification, this application was 
explored.  
The first step was to design two libraries based on amino acids of the protein PAB and 
drugs that bind naturally to the domain II of HSA. We focused on targeting domain II, because it 
is important have the domain III of HSA available to bind to FcRn. 
The libraries were synthesized using the Ugi and Triazine reactions, producing 152 
different ligands, 88 ligands from the Ugi library and 64 ligands from the Triazine library.  
The libraries were screened against pure HSA in 10mM Sodium Phosphate, NaCl 
150mM at pH 7.4 and at pH 6.0. A total of 17 ligands were selected on the basis of a high 
percentage of binding to HSA (>50%) at both pH 6.0 and 7.4, being 4 of the Ugi library and 13 
of the Triazine library. The synthetic ligands showed a percent bound to HSA higher at pH 7.4, 
in this way, this pH was chosen to continue the studies to test the selectivity of the ligands, in 
order to re-synthesize and re-screen the lead ligands to HSA and confirm the reproducibility of 
the results.  
Therefore, the 152 ligands from the two libraries were screened for binding IgG at 
physiological conditions.  After the screening against IgG, a selectivity criterion was used in this 
work, and 13 ligands (5 of Ugi library and 8 of Triazine library) were chosen to proceed.  The 13 
ligands were re-synthesized and re-screened against HSA and IgG, and two ligands showed 
consistent results. 
The two ligands, A3A2 and A6A5, were packed in small column and re-screened in 
individual assays to bind HSA and IgG at pH 7.4. The results remained consistent; the A3A2 
obtained a percentage of 100% and 43% of bound HSA and IgG, respectively. The A6A5 ligand 
obtained a percentage of 99% and 53% of bound HSA and IgG, respectively. 
In conclusion, the synthetic ligands based on the Ugi and Triazine reactions have 
been successfully used to bind to HSA at pH 7.4, and the 96-well screening format proved to be 
a reproducible, easy to perform and time saving protocol. Although the binding conditions were 
very efficient using 10mM Sodium Phosphate 150mM NaCl at pH 7.4, it is necessary to optimize 
the means to reduce the binding to IgG, in order to increase selectivity. The elution step also 
needs to be optimized to recovery HSA, through a strategy utilizing conditions that promote a 
decrease of hydrophobic interaction between the ligand and the target. 
These synthetic ligands appear as a promising alternative to purify HSA, due to its 
resistance, long life, and low cost.  
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